var title_f21_43_22192="1-hand method PI";
var content_f21_43_22192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    One-handed chest compressions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressing on the chest for CPR is called doing \"compressions.\" To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim and place the heel of 1 hand on the center of the victim's chest. Holding your arm straight, press on the chest. Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim's chest drops down at least 2 inches (5 centimeters) under your weight with each push. Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22192=[""].join("\n");
var outline_f21_43_22192=null;
var title_f21_43_22193="mRNA processing";
var content_f21_43_22193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Post-transcription modification of mRNA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pre-mRNA transcripts are unsuitable for protein translation. Introns must be removed through a process called splicing to align the exons for their subsequent translation. The spliced RNA is an unstable molecule, with highly reactive moieties at both the 5' and 3' ends. Addition of the 5' cap and the 3' poly-A tail are critical for stabilization of RNA and for their subsequent metabolism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22193=[""].join("\n");
var outline_f21_43_22193=null;
var title_f21_43_22194="Male anatomy PI";
var content_f21_43_22194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Male reproductive anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows what a man's reproductive organs look like.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22194=[""].join("\n");
var outline_f21_43_22194=null;
var title_f21_43_22195="Patient information: Coughing up blood (The Basics)";
var content_f21_43_22195=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16905\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"         Normal lungs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/28/24002\">",
"         Patient information: Acute bronchitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/25/39314\">",
"         Patient information: Bronchiectasis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40850\">",
"         Patient information: Bronchiectasis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/59/5043\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/7/13427\">",
"         Patient information: Cough in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/57/20371\">",
"         Patient information: Cystic fibrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/34/35363\">",
"         Patient information: Lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/38/36450\">",
"         Patient information: Whooping cough (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/34/28195\">",
"         Patient information: Chronic cough in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/13/1236\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/14/32993\">",
"         Patient information: Flexible bronchoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Coughing up blood (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/coughing-up-blood-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H81822447\">",
"      <span class=\"h1\">",
"       What is coughing up blood?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Coughing up blood is when people cough up blood (by itself) or blood mixed with mucus. When mucus has blood in it, it can have streaks of blood, or the mucus can turn red or pink. The term doctors use for coughing up blood is &ldquo;hemoptysis.&rdquo; Coughing up blood can happen in adults and older children, but it is uncommon in young children.",
"     </p>",
"     <p>",
"      When a person coughs up blood, it means the blood is coming from their airways or lungs (",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"       figure 1",
"      </a>",
"      ). Bleeding from the nose or stomach can look like coughing up blood, but it is not the same.",
"     </p>",
"     <p>",
"      If people cough up a lot of blood, doctors call it &ldquo;massive hemoptysis.&rdquo; This can be a medical emergency. This article discusses coughing up blood that is not a medical emergency.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81822462\">",
"      <span class=\"h1\">",
"       What causes people to cough up blood?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In adults, there are many causes of coughing up blood, but the most common causes are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bronchitis &ndash; Bronchitis means inflammation of the bronchi. The bronchi are the tubes that carry air into the lungs (",
"        <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"         figure 1",
"        </a>",
"        ). There are 2 types of bronchitis. &ldquo;Acute&rdquo; bronchitis is an infection of the bronchi. &ldquo;Chronic&rdquo; bronchitis is a condition in which the airways (tubes that carry air within the lungs) get damaged.",
"       </li>",
"       <li>",
"        Infections of the lungs, such as pneumonia",
"       </li>",
"       <li>",
"        Bronchiectasis &ndash; This is a condition in which the airways are damaged and get infected easily. It has different causes.",
"       </li>",
"       <li>",
"        Cancer that affects the bronchi or airways",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In children, the most common causes of coughing up blood are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An infection of the bronchi, airways, or lungs",
"       </li>",
"       <li>",
"        Having an object or piece of food stuck in the airway. The object might be stuck for days or weeks before a child starts coughing up blood.",
"       </li>",
"       <li>",
"        Bronchiectasis &ndash; In children, this is usually caused by &ldquo;cystic fibrosis,&rdquo; which is a condition some children are born with. Cystic fibrosis causes thick mucus to build up in the lungs, which leads to frequent lung infections.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81822477\">",
"      <span class=\"h1\">",
"       Should I call a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Any time you or your child coughs up blood or mucus mixed with blood, call the doctor or nurse right away.",
"     </p>",
"     <p>",
"      Let the doctor or nurse know if you remember seeing your child choke on something, even if it was days or weeks ago.",
"     </p>",
"     <p>",
"      If you cough up a very large amount of blood (about 1 cup or more), or are having trouble breathing, call 9-1-1 for ambulance.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81822492\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will ask about your symptoms and do an exam. Based on your symptoms and other factors, he or she might do tests. These tests can help your doctor or nurse find out why you&rsquo;re bleeding and where the bleeding is coming from.",
"     </p>",
"     <p>",
"      Different tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        Lab tests &ndash; These might include blood tests or tests on a sample of the mucus you cough up.",
"       </li>",
"       <li>",
"        Bronchoscopy &ndash; This is a procedure in which a doctor uses a thin tube (called a &ldquo;bronchoscope&rdquo;) to look inside your airways.",
"       </li>",
"       <li>",
"        A CT scan &ndash; This is an imaging test that creates pictures of the inside of your body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81822509\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to stop coughing up blood?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Teenagers and adults who have streaks of blood in their mucus can try to quiet their cough by using an over-the-counter cough medicine.",
"     </p>",
"     <p>",
"      But do NOT give any cough or cold medicines to young children. These medicines are unlikely to help and can have serious side effects in young children.",
"     </p>",
"     <p>",
"      If you smoke cigarettes, the most helpful thing you can do is stop smoking.",
"     </p>",
"     <p>",
"      If you take a medicine that keeps blood clots from forming (a &ldquo;blood thinning&rdquo; medicine), let your doctor or nurse know. He or she might change your dose.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81822524\">",
"      <span class=\"h1\">",
"       How is coughing up blood treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms are mild and happen only with a common cold, you might not need treatment.",
"     </p>",
"     <p>",
"      If you do need treatment, your doctor will treat the condition that&rsquo;s causing you to cough up blood. He or she can also help stop the bleeding by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Prescribing a cough medicine to keep you from coughing",
"       </li>",
"       <li>",
"        Prescribing an antibiotic if you have bronchiectasis or an infection",
"       </li>",
"       <li>",
"        Doing a procedure during bronchoscopy to stop the bleeding",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81822539\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       Patient information: Cough in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=see_link\">",
"       Patient information: Acute bronchitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       Patient information: Lung cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=see_link\">",
"       Patient information: Cystic fibrosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       Patient information: Whooping cough (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/25/39314?source=see_link\">",
"       Patient information: Bronchiectasis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=see_link\">",
"       Patient information: Bronchiectasis in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"       Patient information: Chronic cough in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"       Patient information: Flexible bronchoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/43/22195?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16905 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22195=[""].join("\n");
var outline_f21_43_22195=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822447\">",
"      What is coughing up blood?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822462\">",
"      What causes people to cough up blood?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822477\">",
"      Should I call a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822492\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822509\">",
"      Is there anything I can do on my own to stop coughing up blood?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822524\">",
"      How is coughing up blood treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81822539\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"      Normal lungs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=related_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/25/39314?source=related_link\">",
"      Patient information: Bronchiectasis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=related_link\">",
"      Patient information: Bronchiectasis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=related_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=related_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22196="Carbamide peroxide: Patient drug information";
var content_f21_43_22196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carbamide peroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16867?source=see_link\">",
"     see \"Carbamide peroxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/30/41442?source=see_link\">",
"     see \"Carbamide peroxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Auraphene B&reg; [OTC];",
"     </li>",
"     <li>",
"      Auro&reg; [OTC];",
"     </li>",
"     <li>",
"      Cankaid&reg; [OTC];",
"     </li>",
"     <li>",
"      Debrox&reg; [OTC];",
"     </li>",
"     <li>",
"      E-R-O&reg; [OTC];",
"     </li>",
"     <li>",
"      Gly-Oxide&reg; [OTC];",
"     </li>",
"     <li>",
"      Murine&reg; Ear Wax Removal Kit [OTC];",
"     </li>",
"     <li>",
"      Murine&reg; Ear [OTC];",
"     </li>",
"     <li>",
"      Otix&reg; [OTC];",
"     </li>",
"     <li>",
"      Wax Away [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to soften earwax so it may be taken out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mouth irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carbamide peroxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear drops:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703514",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Ear drainage, ear pain, a hole in the eardrum, or a rash in the ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699025",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear drops:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11484 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22196=[""].join("\n");
var outline_f21_43_22196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145723\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019706\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019705\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019710\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019711\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019713\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019708\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019709\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019714\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019715\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16867?source=related_link\">",
"      Carbamide peroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/30/41442?source=related_link\">",
"      Carbamide peroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22197="Clonazepam: Patient drug information";
var content_f21_43_22197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clonazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     see \"Clonazepam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"     see \"Clonazepam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      KlonoPIN&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clonazepam&reg;;",
"     </li>",
"     <li>",
"      Clonapam;",
"     </li>",
"     <li>",
"      Clonazepam-R;",
"     </li>",
"     <li>",
"      CO Clonazepam;",
"     </li>",
"     <li>",
"      Dom-Clonazepam;",
"     </li>",
"     <li>",
"      Dom-Clonazepam-R;",
"     </li>",
"     <li>",
"      Mylan-Clonazepam;",
"     </li>",
"     <li>",
"      Novo-Clonazepam;",
"     </li>",
"     <li>",
"      PHL-Clonazepam;",
"     </li>",
"     <li>",
"      PHL-Clonazepam-R;",
"     </li>",
"     <li>",
"      PMS-Clonazepam;",
"     </li>",
"     <li>",
"      PRO-Clonazepam;",
"     </li>",
"     <li>",
"      ratio-Clonazepam;",
"     </li>",
"     <li>",
"      Riva-Clonazepam;",
"     </li>",
"     <li>",
"      Rivotril&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Clonazepam;",
"     </li>",
"     <li>",
"      ZYM-Clonazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat intense manic flare-ups.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat multifacial tic problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat painful nerve diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701839",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clonazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not push the tablet out of the foil when opening. Use dry hands to take it from the foil. Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use oral-disintegrating tablet right after opening. Throw away any part of opened pouch that is not used.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12282 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22197=[""].join("\n");
var outline_f21_43_22197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263353\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017282\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017281\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017286\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017287\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017289\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017284\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017285\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017290\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017291\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=related_link\">",
"      Clonazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=related_link\">",
"      Clonazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22198="Ethinyl estradiol and levonorgestrel: Patient drug information";
var content_f21_43_22198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and levonorgestrel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/2/17450?source=see_link\">",
"     see \"Ethinyl estradiol and levonorgestrel: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altavera&trade;;",
"     </li>",
"     <li>",
"      Amethia&trade;;",
"     </li>",
"     <li>",
"      Amethia&trade; Lo;",
"     </li>",
"     <li>",
"      Amethyst&trade;;",
"     </li>",
"     <li>",
"      Aviane&trade;;",
"     </li>",
"     <li>",
"      camrese&trade;;",
"     </li>",
"     <li>",
"      Chateal&trade;;",
"     </li>",
"     <li>",
"      Enpresse&reg;;",
"     </li>",
"     <li>",
"      Falmina&trade;;",
"     </li>",
"     <li>",
"      Introvale&trade;;",
"     </li>",
"     <li>",
"      Jolessa&trade;;",
"     </li>",
"     <li>",
"      Kurvelo&trade;;",
"     </li>",
"     <li>",
"      Lessina&reg;;",
"     </li>",
"     <li>",
"      Levonest&trade;;",
"     </li>",
"     <li>",
"      Levora&reg;;",
"     </li>",
"     <li>",
"      LoSeasonique&reg;;",
"     </li>",
"     <li>",
"      Lutera&reg;;",
"     </li>",
"     <li>",
"      Lybrel&reg;;",
"     </li>",
"     <li>",
"      Marlissa;",
"     </li>",
"     <li>",
"      Myzilra&trade;;",
"     </li>",
"     <li>",
"      Nordette&reg; 28 [DSC];",
"     </li>",
"     <li>",
"      Orsythia&trade;;",
"     </li>",
"     <li>",
"      Portia&reg;;",
"     </li>",
"     <li>",
"      Quasense&reg;;",
"     </li>",
"     <li>",
"      Seasonale&reg; [DSC];",
"     </li>",
"     <li>",
"      Seasonique&reg;;",
"     </li>",
"     <li>",
"      Sronyx&reg;;",
"     </li>",
"     <li>",
"      Trivora&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alesse&reg;;",
"     </li>",
"     <li>",
"      Aviane&reg;;",
"     </li>",
"     <li>",
"      Min-Ovral&reg;;",
"     </li>",
"     <li>",
"      Seasonale&reg;;",
"     </li>",
"     <li>",
"      Triphasil&reg;;",
"     </li>",
"     <li>",
"      Triquilar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691841",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat women with hypogonadism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heavy bleeding during monthly periods (menstruation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, levonorgestrel, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your monthly cycle is 28 days and you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a cycle longer than 91 days and you miss one period, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12449 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22198=[""].join("\n");
var outline_f21_43_22198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168331\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168332\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027236\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027238\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027237\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027242\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027243\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027245\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027240\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027241\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027246\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027247\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/2/17450?source=related_link\">",
"      Ethinyl estradiol and levonorgestrel: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22199="Pentamidine: Drug information";
var content_f21_43_22199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentamidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/2/39973?source=see_link\">",
"    see \"Pentamidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"    see \"Pentamidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nebupent&reg;;",
"     </li>",
"     <li>",
"      Pentam&reg; 300",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent;",
"     </li>",
"     <li>",
"      Antiprotozoal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PCP:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      FDA-approved labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Inhalation: 300 mg every 4 weeks via Respirgard&reg; II nebulizer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.M., I.V.: 4 mg/kg once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CDC recommendation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Inhalation: 300 mg monthly via Respirgard&reg; II nebulizer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 3-4 mg/kg once daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      AIDSinfo guidelines (2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Inhalation: 300 mg/dose monthly via Respirgard&reg; II nebulizer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 4 mg/kg once daily, 3 mg/kg may be used by some clinicians",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cutaneous leishmaniasis (unlabeled use; CDC recommendation):",
"     </b>",
"     I.M., I.V.: 2-3 mg/kg once daily or every second day for 4-7 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Trypanosomiasis (unlabeled use; CDC recommendation):",
"     </b>",
"     I.M.: 4 mg/kg once daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"      see \"Pentamidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PCP:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      FDA-approved labeling:",
"     </i>",
"     Children &gt;4 months: Treatment: I.M., I.V.: 4 mg/kg once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CDC recommendation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention (children &ge;5 years): Inhalation: 300 mg/dose monthly via Respirgard&reg; II nebulizer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 3-4 mg/kg once daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      AIDSinfo  guidelines (2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Children &ge;5 years: Inhalation: 300 mg/dose monthly via Respirgard&reg; II nebulizer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 4 mg/kg once daily, if clinical improvement may change to atovaquone after 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PCP prevention in pediatric oncology patients (age &lt;5 years, intolerant to trimethoprim-sulfamethoxazole; unlabeled use):",
"     </b>",
"     4 mg/kg I.V. once monthly (Kim, 2008; Prasad, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cutaneous leishmaniasis (unlabeled use; CDC recommendation):",
"     </b>",
"     I.M., I.V.: 2-3 mg/kg once daily or every second day for 4-7 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Trypanosomiasis (unlabeled use; CDC recommendation):",
"     </b>",
"     I.M.: 4 mg/kg once daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F207954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.: The FDA-approved labeling recommends that caution should be used in patients with renal impairment; however, no specific dosage adjustment guidelines are available. The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer 4 mg/kg every 36 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute and peritoneal dialysis: Administer 4 mg/kg every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 4 mg/kg every 48 hours, after dialysis on dialysis days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 4 mg/kg every 24-36 hours.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as isethionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentam&reg; 300: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, for nebulization, as isethionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nebupent&reg;: 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use NS to reconstitute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: Deliver via Respirgard&reg; II nebulizer until nebulizer is emptied (30-45 minutes). Administer at a flow rate of 5-7 L/minute from a 40-50 pound-per-square inch (PSI) oxygen or air source. A 40-50 PSI air compressor can be used alternatively, with a set flow rate at 5-7 L/minute or a set pressure of 22-25 PSI. Air compressors &lt;20 PSI should not be used. Use appropriate precautions to minimize exposure to healthcare personnel; refer to individual institutional policy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse slowly over 60-120 minutes. Avoid extravasation; assess catheter position before and during infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer deep I.M.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F207979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS (do not use NS for initial reconstitution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diltiazem, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, fluconazole, foscarnet, linezolid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.: Treatment of pneumonia caused by",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: Prevention of PCP in high-risk, HIV-infected patients either with a history of PCP or with a CD4+ count &le;200/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F207969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of PCP in nonHIV-infected patients; treatment of African trypanosomiasis, cutaneous leishmaniasis, and amebic meningoencephalitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Aerosol:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (66%), fever (51%), dizziness/lightheadedness (45%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1% to 63%), dyspnea (48%), wheezing (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, oral candida, taste alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, chest pain, pharyngitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes infection, influenza, night sweats",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Local reactions at I.M. injection site (11%; includes sterile abscess, necrosis, pain, induration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal function impaired (29%), creatinine increased (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion/hallucinations (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/anorexia (6%), taste alteration (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (10%), thrombocytopenia (3%), anemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Azotemia (9%), BUN increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Aerosol or injection:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, allergic reaction, anaphylaxis, anxiety, arthralgia, asthma, blepharitis, blurred vision, bronchitis, bronchospasm, cardiac arrhythmia, central venous line related sepsis, cerebrovascular accident, chest tightness, chills, clotting time prolonged, CMV infection, colitis, confusion, congestion (chest, nasal), conjunctivitis, cough, cryptococcal meningitis, cyanosis, defibrination, depression, dermatitis, desquamation, diabetes mellitus, diabetic ketoacidosis, diarrhea, dizziness, drowsiness, dyspepsia, dyspnea, emotional lability, eosinophilia, erythema, esophagitis, extrapulmonary pneumocystosis, extravasation (tissue ulceration, necrosis, and/or sloughing), facial edema, flank pain, gait unsteady, gagging, gingivitis, headache, hearing loss, hematochezia, hematuria, hemoptysis, hepatic dysfunction, hepatitis, hepatomegaly, histoplasmosis, hyperglycemia, hyperkalemia, hypersalivation, hypertension, hyperventilation, hypesthesia, hypocalcemia, hypomagnesemia, incontinence, insomnia, laryngitis, laryngospasm, leg edema, melena, memory loss, nephritis, nervousness, neuralgia, neuropathy, neutropenia, night sweats, palpitation, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, phlebitis, pleuritis, pneumonitis (eosinophilic or interstitial), pneumothorax, pruritus, rales, renal dysfunction, renal failure, rhinitis, seizure, splenomegaly, Stevens-Johnson syndrome, ST segment abnormal, syncope, syndrome of inappropriate antidiuretic hormone (SIADH), tachycardia, tachypnea, temperature abnormal, torsade de pointes, tremor, vasodilation, vasculitis, ventricular tachycardia, vertigo, vomiting, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentamidine isethionate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Severe hypotension (some fatalities) has been observed, even after a single dose. May occur with either I.V. or I.M administration, although more common with rapid I.V. administration. Monitor blood pressure during (and after) infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: May cause QT prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stevens-Johnson syndrome: Has been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use inhalation formulation with caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; hyper-/hypotension and arrhythmia, including ventricular tachycardia (eg, torsade de pointes) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; hyper-/hypoglycemia and pancreatic islet cell necrosis with hyperinsulinemia has been reported. Symptoms may occur months after therapy; monitor blood glucose daily on therapy and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disorders: Use with caution in patients with current evidence and/or prior history of hematologic disorders; anemia, leukopenia and/or thrombocytopenia have been reported. Concurrent use with other bone marrow suppressants may increase the risk for myelotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels; acute pancreatitis (with fatality) has been reported. Discontinue inhalational pentamidine if signs/symptoms of acute pancreatitis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxic drugs: Concurrent use with other nephrotoxic drugs may increase the risk for nephrotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhalation: May induce bronchospasm or cough, especially in patients with a smoking or asthma history (an inhaled bronchodilator prior to pentamidine may ameliorate symptoms). Acute PCP may develop despite aerosolized pentamidine prophylaxis. Although rare, extrapulmonary PCP disease may occur and has been associated with aerosolized pentamidine. Use appropriate precautions to minimize exposure to healthcare personnel; refer to individual institutional policy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V.: Avoid extravasation. May cause tissue ulceration, necrosis, and/or sloughing. If extravasation occurs, treat symptomatically. Assess catheter position before and during infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F207967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F207945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression or aggravate hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7305395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies were not conducted by the manufacturer; therefore, pentamidine is classified pregnancy category C. In postmarketing studies, pentamidine was embryocidal but not teratogenic when administered to animals. Pentamidine crosses the human placenta. Administration via the aerosolized route may minimize maternal serum concentrations. Concern regarding occupational exposure of pregnant healthcare workers has been discussed in the literature. Pregnant healthcare workers should avoid aerolized exposure if possible. If avoidance is not possible, they should wear a mask and gloves and ensure proper ventilation. Pentamidine may be used in pregnancy for prophylaxis or treatment of PCP if the patient is unable to take first line medications.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7305398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if pentamidine is excreted in human milk and use of pentamidine during breast-feeding is not recommended by the manufacturer. In the United States where formula is accessible, affordable, safe, and sustainable, complete avoidance of breast-feeding by HIV-infected women is recommended by the AAP and the CDC to decrease potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Nebupent Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (1): $118.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Pentam Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (1): $118.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, renal function tests, blood glucose, serum potassium and calcium, CBC and platelets; ECG, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5505779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pentacarinat (AT, BB, BE, BG, BM, BS, BZ, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GY, HK, HN, IE, IT, JM, MT, NL, NO, NZ, PR, PT, RU, SE, SK, SR, TH, TR, TT);",
"     </li>",
"     <li>",
"      Pentacarinate (GR);",
"     </li>",
"     <li>",
"      Pentam 300 (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with microbial RNA/DNA, phospholipids and protein synthesis, through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Well absorbed; Inhalation: Limited systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : I.V.: 286-1356 L; I.M.: 1658-3790 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 5-8 hours; I.M.: 7-11 hours; may be prolonged with severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (I.V.: &le;12% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 73, 160.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Amebic Meningoencephalitis, Primary and Granulomatous.&rdquo; Available at",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/AmebicMeningoencephalitis.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/AmebicMeningoencephalitis.pdf",
"      </a>",
"      . Last accessed September 15, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-176. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/OI_Guidelines_Pediatrics.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/OI_Guidelines_Pediatrics.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-194. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Leishmania.&rdquo; Available at",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Leishmania.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Leishmania.pdf",
"      </a>",
"      . Last accessed September 15, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;",
"      <i>",
"       Pneumocystis jiroveci",
"      </i>",
"      (formerly",
"      <i>",
"       carinii",
"      </i>",
"      ) Pneumonia (PCP).&rdquo; Available at",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf",
"      </a>",
"      . Last accessed September 15, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Trypanosomiasis.&rdquo; Available at",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Trypanosomiasis.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Trypanosomiasis.pdf",
"      </a>",
"      . Last accessed September 15, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Comtois R, Pouliot J, Gervais S, et al, &ldquo;High Pentamidine Levels Associated With Hypoglycemia and Azotemia in a Patient With",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 1992, 15(6):523-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/1424505/pubmed\" id=\"1424505\" target=\"_blank\">",
"        1424505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conte JE Jr, &ldquo;Pharmacokinetics of Intravenous Pentamidine in Patients With Normal Renal Function or Receiving Hemodialysis,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1991, 163(1):169-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/1984463/pubmed\" id=\"1984463\" target=\"_blank\">",
"        1984463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortese LM, Gasser RA, Jr, Bjornson DC, et al, &ldquo;Prolonged Recurrence of Pentamidine-Induced Torsade de Pointes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(11):1365-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/1477438/pubmed\" id=\"1477438\" target=\"_blank\">",
"        1477438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goa KL and Campoli-Richards DM, &ldquo;Pentamidine Isethionate. A Review of Its Antiprotozoal Activity, Pharmacokinetic Properties and Therapeutic Use in",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1987, 33(3):242-58.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hand IL, Wiznia AA, Porricolo M, et al, &ldquo;Aerosolized Pentamidine for Prophylaxis of",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Infants With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1994, 13(2):100-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/8190532/pubmed\" id=\"8190532\" target=\"_blank\">",
"        8190532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes WT, &ldquo;",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia: New Approaches to Diagnosis, Treatment, and Prevention,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1991, 10(5):391-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/2067889/pubmed\" id=\"2067889\" target=\"_blank\">",
"        2067889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ito S and Koren G, &ldquo;Estimation of Fetal Risk From Aerosolized Pentamidine in Pregnant Healthcare Workers,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1994, 106(5):1460-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/7956402/pubmed\" id=\"7956402\" target=\"_blank\">",
"        7956402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim SY, Dabb AA, Glenn DJ, et al, &ldquo;Intravenous Pentamidine is Effective as Second Line Pneumocystis Pneumonia Prophylaxis in Pediatric Oncology Patients,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(4):779-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/17635000/pubmed\" id=\"17635000\" target=\"_blank\">",
"        17635000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masur H, &ldquo;Prevention and Treatment of",
"      <i>",
"       Pneumocystis",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(26):1853-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/1448123/pubmed\" id=\"1448123\" target=\"_blank\">",
"        1448123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk JP and Benfield P, &ldquo;Inhaled Pentamidine. An Overview of Its Pharmacological Properties and a Review of Its Therapeutic Use in",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(5):741-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/2191850/pubmed\" id=\"2191850\" target=\"_blank\">",
"        2191850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelucio MT, Rothenhaus T, Smith M, et al, &ldquo;Fatal Pancreatitis as a Complication of Therapy for HIV Infection,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(5):633-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/8530781/pubmed\" id=\"8530781\" target=\"_blank\">",
"        8530781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prasad P, Nania JJ, and Shankar SM, &ldquo;Pneumocystis Pneumonia in Children Receiving Chemotherapy,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(4):896-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/17458875/pubmed\" id=\"17458875\" target=\"_blank\">",
"        17458875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sattler FR, Cowan R, Nielsen DM, et al, &ldquo; Trimethoprim-Sulfamethoxazole Compared With Pentamidine for Treatment of",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1988, 109(4):280-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/3260759/pubmed\" id=\"3260759\" target=\"_blank\">",
"        3260759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh G, el-Gadi SM, and Sparks RA, &ldquo;Pancreatitis Associated With Aerosolized Pentamidine,&rdquo;",
"      <i>",
"       Genitourin Med",
"      </i>",
"      , 1995, 71(2):130-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/7744406/pubmed\" id=\"7744406\" target=\"_blank\">",
"        7744406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomblyn M, Chiller T, Einsele H, et al, &ldquo;Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(10):1143-238.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/43/22199/abstract-text/19747629/pubmed\" id=\"19747629\" target=\"_blank\">",
"        19747629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9752 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22199=[""].join("\n");
var outline_f21_43_22199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207948\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207973\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207952\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207965\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207953\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207954\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207928\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207913\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207932\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207979\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207931\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207969\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207971\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207935\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207917\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207967\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207922\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207945\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207924\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305395\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207959\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305398\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323659\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207926\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505779\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207916\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207934\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/2/39973?source=related_link\">",
"      Pentamidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=related_link\">",
"      Pentamidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22200="Blocked APB tutorial";
var content_f21_43_22200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blocked atrial premature beat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 148px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonconducted or blocked atrial premature beats occur when there is premature activation of the atrial myocardium from an ectopic atrial focus at a time when the atrioventricular node is still refractory due to the previous sinus beat. Since the block is in the atrioventricular node, there is an isolated or nonconducted P wave seen on the ECG. In this case, the P wave is located within T wave of the first beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22200=[""].join("\n");
var outline_f21_43_22200=null;
var title_f21_43_22201="Pathology of lung malignancies";
var content_f21_43_22201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology of lung malignancies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/43/22201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22201/contributors\">",
"     Henry D Tazelaar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/43/22201/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22201/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22201/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/43/22201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22201/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/43/22201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the most common cancer worldwide, with an estimated 1,600,000 new cases and 1,380,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic features of the major lung malignancies will be reviewed here. Clinical features, diagnosis, and management of patients with the different lung malignancies are discussed in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION SCHEMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification of lung carcinomas by histopathologic subtype provides important information about prognosis and is necessary for optimal treatment. Traditionally, the classification of lung carcinoma has been based solely on evaluation of routinely stained biopsies or cytologic preparations. Increasingly, however, ancillary tests such as immunohistochemistry are being used to aid pathologists in diagnosis of subtypes. The classification scheme for lung carcinoma is therefore in a state of flux with the 2004 World Health Organization (WHO) providing the framework for classification, but the tools used to arrive at the diagnosis now supersede what that classification scheme endorsed. &nbsp;",
"   </p>",
"   <p>",
"    The 2004 World Health Organization (WHO) schema of lung tumors has been the foundation for lung cancer classification (",
"    <a class=\"graphic graphic_table graphicRef59692 \" href=\"UTD.htm?19/17/19740\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ]. This incorporated a number of developments, including recognition of lung carcinoma heterogeneity, the introduction of diagnostic immunohistochemical staining (IHC) techniques for the routine diagnosis of some neuroendocrine tumors, and the recognition of newly described entities such as fetal adenocarcinoma, cystic mucinous tumors, and large cell neuroendocrine carcinoma.",
"   </p>",
"   <p>",
"    In 2011, a multidisciplinary expert panel representing the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) proposed a major revision of the classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/3\">",
"     3",
"    </a>",
"    ]. These changes primarily affect the classification of adenocarcinoma and its distinction from squamous cell carcinoma.",
"   </p>",
"   <p>",
"    The rationale for these",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    recommendations is based upon several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advances in understanding the specific molecular pathways that drive malignancy have opened up new pathways for treatment, and molecular characterization of patients with adenocarcinoma is resulting in the use of agents with high levels of antitumor activity. As an example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the preferred initial treatment for patients with metastatic lung adenocarcinoma whose tumors have characteristic activating mutation in EGFR. Targeted therapy is also being developed for those with adenocarcinomas whose tumors harbor the EML4-ALK translocation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Distinguishing squamous carcinoma from other non-small carcinomas, particularly adenocarcinoma, is important for patients with advanced stage disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/4-6\">",
"       4-6",
"      </a>",
"      ] as certain chemotherapeutic agents are contraindicated for patients with squamous histology. The 2004 WHO classification did not address how this distinction was to be made on small biopsies and specifically endorsed lumping tumors under the &ldquo;non small cell carcinoma&rdquo; rubric. The new classification scheme offers guidelines for how to use a panel of immunohistochemical stains (eg, p63, TTF-1, cytokeratin",
"      <span class=\"nowrap\">",
"       5/6)",
"      </span>",
"      when obvious features of a specific line of differentiation are not apparent on a small biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Effect of histology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiographic abnormalities, particularly the appearance of small carcinomas with a ground glass appearance, help to define a subset of patients with adenocarcinoma, who have an excellent prognosis with complete surgical resection. Less extensive surgery may be adequate treatment in such cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion incorporates that proposed revision and provides correlation with the WHO schema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma is the most common type of lung cancer in contemporary series, accounting for approximately one-half of lung cancer cases. The increased incidence of adenocarcinoma is thought to be due to the introduction of low-tar filter cigarettes in the 1960s, although such causality is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic diagnosis requires evidence of either neoplastic gland formation or intracytoplasmic mucin (",
"    <a class=\"graphic graphic_picture graphicRef71512 \" href=\"UTD.htm?11/53/12120\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50555 \" href=\"UTD.htm?28/10/28839\">",
"     picture 2",
"    </a>",
"    ). There is significant variation in the extent and architecture of neoplastic gland formation, ranging from well-formed acini to more papillary and even cribriform types. The solid type of adenocarcinoma lacks the architectural characteristics of better differentiated tumors and is indistinguishable from large cell undifferentiated carcinoma except for the presence of intracellular mucin. The detection of intracellular mucin requires special histochemical stains, such as mucicarmine or Periodic Acid-Schiff (PAS) (",
"    <a class=\"graphic graphic_picture graphicRef67385 \" href=\"UTD.htm?12/28/12743\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1177650\">",
"    <span class=\"h2\">",
"     2004 WHO classification of adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2004 World Health Organization schema (",
"    <a class=\"graphic graphic_table graphicRef59692 \" href=\"UTD.htm?19/17/19740\">",
"     table 1",
"    </a>",
"    ), adenocarcinoma is divided into a number of subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ]. Although it remains to be seen whether the WHO adopts the new classification scheme for adenocarcinoma, the 2004 classification defined some entities more specifically, and introduced some new entities, most of which [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ] are retained in the new proposed classification. Among the more notable are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restricting the definition of bronchioloalveolar carcinoma (BAC) &ndash; In the 2004 WHO classification, the term BAC is restricted to tumors in which the characteristic lepidic growth pattern (growth along intact alveolar septae) comprises the entire tumor. BAC therefore lacks any stromal, pleural, or lymphatic invasion, although fibrous tissue or a chronic inflammatory cell infiltrate may thicken the alveolar septa. Both mucinous and non-mucinous subtypes are recognized. In the new classification scheme, these tumors have been renamed as adenocarcinoma in situ (see below).",
"     </li>",
"     <li>",
"      Mucinous adenocarcinomas of non-BAC type &ndash; Mucin may be a prominent finding in rare examples of non-bronchioloalveolar lung carcinomas. Reported cases vary in aggressiveness from low grade tumors of uncertain malignant potential to high grade adenocarcinomas with signet ring cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Of particular interest is a group of mucinous cystic tumors designated by a confusing array of terms analogous to those used for similar tumors occurring in non-pulmonary sites (eg, mucinous cystadenoma, mucinous cystic tumor of borderline malignancy, mucinous [\"colloid\"] carcinoma) (",
"      <a class=\"graphic graphic_picture graphicRef79850 \" href=\"UTD.htm?43/21/44375\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/9\">",
"       9",
"      </a>",
"      ]. Most of these tumors present as asymptomatic, solitary, peripherally situated cystic masses (",
"      <a class=\"graphic graphic_picture graphicRef75968 \" href=\"UTD.htm?9/11/9392\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Resection of colloid carcinoma is generally curative, but several cases with distant metastases to the brain or bone have been reported. Therefore, mucinous cystic tumors are best viewed as low grade variants of adenocarcinoma rather than benign neoplasms. Signet ring cell cancers usually behave aggressively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/10\">",
"       10",
"      </a>",
"      ]. Again, distinction from metastatic adenocarcinoma can occasionally be problematic. Of the common lung cancers, BAC has the lowest association with chronic cigarette smoking.",
"     </li>",
"     <li>",
"      Papillary adenocarcinoma &ndash; In the past, tumors with prominent papillary architecture were classified as BAC. There is increasing evidence, however, that tumors with papillae with secondary and tertiary branching of the papillae may have a worse prognosis than other adenocarcinomas. In the 2004 system, papillary adenocarcinomas are classified separately [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. In the new classification scheme, papillary tumors are divided into papillary and micropapillary, the latter having a particularly poor prognosis.",
"     </li>",
"     <li>",
"      Fetal adenocarcinoma &ndash; Fetal adenocarcinomas, formerly referred to as endodermal tumors resembling fetal lung, are considered by some to represent a \"monophasic\" subset of pulmonary blastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Classical pulmonary blastoma is a biphasic tumor in which fetal adenocarcinoma is accompanied by a primitive mesenchymal component resembling the blastomatous component of renal Wilms tumors. Regardless of their true histogenesis, fetal adenocarcinomas have a distinctive histologic appearance and are associated with a better prognosis than typical pulmonary adenocarcinomas. These tumors are composed of relatively bland columnar cells arranged in a complex glandular pattern resembling that seen in the epithelial component of classical pulmonary blastomas and have a striking resemblance to endometrial adenocarcinoma (",
"      <a class=\"graphic graphic_picture graphicRef75932 \" href=\"UTD.htm?18/1/18457\">",
"       picture 6",
"      </a>",
"      ). The cytoplasm of the columnar cells is often vacuolated and clear due to the presence of glycogen. Stains for epithelial mucins are usually negative, or only focally and faintly positive. There is often an associated desmoplastic response, although it tends not to be a prominent feature. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1177702\">",
"    <span class=\"h2\">",
"     2011 IASLC/ATS/ERS classification of adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 schema from the",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    incorporates a number of changes in the classification of patients with adenocarcinoma (",
"    <a class=\"graphic graphic_table graphicRef66033 \" href=\"UTD.htm?14/25/14748\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74747 \" href=\"UTD.htm?31/11/31933\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term bronchioloalveolar carcinoma (BAC) is eliminated. Lesions that were formerly classified as BAC are now placed in one of several categories that appear to correlate with the stages of transformation into widely invasive adenocarcinoma. The early stages of these lesions include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Atypical adenomatous hyperplasia (AAH), an entity that was previously recognized in the WHO system as a preinvasive lesion for lung adenocarcinoma (",
"      <a class=\"graphic graphic_picture graphicRef55484 \" href=\"UTD.htm?19/61/20439\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Adenocarcinoma in situ (AIS) is a localized (&le;3 cm) adenocarcinoma in which growth is restricted to tumor cells growing along alveolar structures (lepidic growth pattern) and lacks any component of invasion. Most AIS tumors are nonmucinous (",
"      <a class=\"graphic graphic_picture graphicRef68223 \" href=\"UTD.htm?14/34/14889\">",
"       picture 8",
"      </a>",
"      ). Mucinous lesions comprise a small subset of such tumors (",
"      <a class=\"graphic graphic_picture graphicRef76968 \" href=\"UTD.htm?2/8/2185\">",
"       picture 9",
"      </a>",
"      ). Observational studies indicate that AIS has a 100 percent cancer-specific survival if completely resected. AIS was previously categorized as bronchioloalveolar carcinoma in the 2004 WHO system.",
"     </li>",
"     <li>",
"      Minimally invasive adenocarcinoma is a small, solitary adenocarcinoma (&le;3 cm) with a predominantly lepidic growth pattern and less than or equal to 5 mm invasion. Most but not all of these lesions are nonmucinous (",
"      <a class=\"graphic graphic_picture graphicRef56935 \" href=\"UTD.htm?32/47/33529\">",
"       picture 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69826 \" href=\"UTD.htm?39/50/40743\">",
"       picture 11",
"      </a>",
"      ). The cancer-free survival in these patients should approach 100 percent with complete surgical resection, based upon observational studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive adenocarcinomas are classified by their predominant pattern. As an example, invasive nonmucinous bronchioloalveolar lesions are classified as invasive adenocarcinoma, lepidic predominant. Other patterns include acinar, papillary, micropapillary, and solid predominant with mucin production (",
"      <a class=\"graphic graphic_picture graphicRef80147 \" href=\"UTD.htm?39/49/40730\">",
"       picture 12",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Invasive mucinous adenocarcinoma (formerly mucinous bronchioloalveolar pattern) is now classified as a separate variant, the implication being that most of what was formerly called mucinous BAC represented invasive adenocarcinomas (",
"      <a class=\"graphic graphic_picture graphicRef58518 \" href=\"UTD.htm?9/10/9383\">",
"       picture 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other variants of invasive adenocarcinoma include colloid, fetal, and enteric adenocarcinoma (",
"      <a class=\"graphic graphic_picture graphicRef67250 \" href=\"UTD.htm?17/43/18106\">",
"       picture 14",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      For lesions without identifiable adenocarcinoma patterns present but in which immunohistochemical stains support the diagnosis of adenocarcinoma, the terminology &ldquo;Non-small cell carcinoma, favor adenocarcinoma&rdquo; is used (",
"      <a class=\"graphic graphic_picture graphicRef79343 \" href=\"UTD.htm?30/26/31145\">",
"       picture 15",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    schema stresses the radiographic correlates of this approach to classification. Examples of this approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The preinvasive AAH and nonmucinous AIS characteristically have a ground glass radiographic appearance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60122 \" href=\"UTD.htm?2/0/2050\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72990 \" href=\"UTD.htm?15/59/16307\">",
"       image 2",
"      </a>",
"      ). Minimally invasive nonmucinous lesions may have a predominantly ground glass appearance with a smaller solid component (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53003 \" href=\"UTD.htm?41/9/42128\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In contrast, mucinous AIS has a solid appearance on imaging (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61743 \" href=\"UTD.htm?11/3/11313\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The radiographic and molecular correlations of the different subtypes are shown in the attached table (",
"      <a class=\"graphic graphic_table graphicRef74551 \" href=\"UTD.htm?15/29/15837\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    document also emphasizes that tissue specimens should be managed not only for pathologic diagnosis, but to preserve tissue for molecular studies. For patients with advanced lung adenocarcinoma, tissue should be tested for the presence of epidermal growth factor receptor (EGFR) mutation status as well as potentially for other molecular abnormalities that could affect subsequent therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H979379364\">",
"    <span class=\"h1\">",
"     ADENOSQUAMOUS CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosquamous carcinomas are defined as tumors comprised of more than 10 percent malignant glandular and squamous components. The mixed histology probably represents the well-recognized heterogeneity of lung carcinomas rather than a prognostically distinct subset [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/16\">",
"     16",
"    </a>",
"    ]. The reported incidence of adenosquamous carcinoma ranges from 0.4 to 4 percent of bronchogenic carcinomas. Adenosquamous carcinoma is an aggressive tumor and appears to have a poorer prognosis than either adenocarcinoma or squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1177018\">",
"    <span class=\"h1\">",
"     SQUAMOUS CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma was the most frequent histologic type of lung tumor in nearly all studies done prior to the mid-1980s. Now, adenocarcinoma is more common than squamous cell carcinoma, particularly in women.",
"   </p>",
"   <p>",
"    Histologic diagnosis of squamous cell carcinoma is predicated upon the presence of keratin production by tumor cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intercellular desmosomes (referred to as \"intercellular bridges\") (",
"    <a class=\"graphic graphic_picture graphicRef72421 \" href=\"UTD.htm?37/35/38453\">",
"     picture 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73209 \" href=\"UTD.htm?15/29/15831\">",
"     picture 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51629 \" href=\"UTD.htm?8/7/8305\">",
"     picture 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78684 \" href=\"UTD.htm?38/1/38933\">",
"     picture 19",
"    </a>",
"    ). Some tumors that are either predominantly spindled (spindle cell variant of pleomorphic carcinoma) or have a characteristic pattern of peripheral palisading may also be classified as squamous cell carcinoma.",
"   </p>",
"   <p>",
"    Historically, most squamous cell carcinoma (60 to 80 percent) arose in the proximal portions of the tracheobronchial tree (",
"    <a class=\"graphic graphic_picture graphicRef59922 \" href=\"UTD.htm?2/10/2211\">",
"     picture 20",
"    </a>",
"    ), although a greater number now occur peripherally. A minority of cases occur peripherally and may be associated with bronchiectatic cavities or scars. Central and peripheral squamous cell carcinomas may show extensive central necrosis with resulting cavitation (",
"    <a class=\"graphic graphic_picture graphicRef60622 \" href=\"UTD.htm?41/22/42340\">",
"     picture 21",
"    </a>",
"    ). A small subset of central, well differentiated squamous cell carcinoma occur as exophytic, endobronchial, papillary lesions (",
"    <a class=\"graphic graphic_picture graphicRef56588 \" href=\"UTD.htm?19/36/20033\">",
"     picture 22",
"    </a>",
"    ). Patients with this unusual variant of squamous cell carcinoma typically present with persistent cough, recurrent hemoptysis, or relapsing pulmonary infections due to airway obstruction. Most patients with exophytic endobronchial squamous cell carcinoma have low stage disease at diagnosis, with a correspondingly good prognosis; five year survival rates are greater than 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several variants of squamous cell carcinoma are included in the WHO classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Papillary &ndash; Papillary squamous cell carcinomas are characterized by exophytic and endobronchial growth patterns in proximal tumors.",
"     </li>",
"     <li>",
"      Small cell &ndash; Some squamous cell carcinomas are composed of small somewhat basaloid-appearing cells resembling classic small cell carcinoma. The distinction between small cell carcinoma and this squamous variant can be made by the nuclear features. Small cell squamous cell carcinoma lacks the even, homogeneous salt and pepper chromatin pattern and nuclear molding seen in small cell carcinomas. The chromatin is more coarse, nuclei contain prominent nucleoli, and the cells usually have more cytoplasm than small cell carcinoma. Immunoperoxidase stains may also be helpful in making this distinction. As an example, thyroid transcription factor-1 (TTF-1) is rarely positive in squamous cell carcinoma, but is expressed by most small cell carcinomas.",
"     </li>",
"     <li>",
"      Clear cell &ndash; Prominent clear cell features may be seen in squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. In a review of 348 consecutive cases of lung carcinoma in 1980, approximately one-third of all primary lung tumors contained foci of clear cell change. In most tumors (70 percent), the clear cell areas involved only 10 to 20 percent of the tumor. Fifteen tumors were composed predominantly of clear cells (one large cell carcinoma, 10 squamous cell carcinomas, and four adenocarcinomas). The clear cell histology in most of these patients prompted a search for a renal primary. The results of this study show that pure clear cell carcinoma is an exceedingly rare tumor (0.3 percent), although clear cell change is relatively common in both squamous cell carcinoma and adenocarcinoma.",
"     </li>",
"     <li>",
"      Basaloid &ndash; Basaloid squamous cell carcinomas are characterized pathologically by prominent peripheral palisading of nuclei.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LARGE CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large cell carcinoma (LCC) is a malignant epithelial neoplasm lacking glandular or squamous differentiation by light microscopy and lacking cytologic features of small cell carcinoma. As the definition implies, LCC is a diagnosis of exclusion intended to include all poorly differentiated NSCLCs that are not further classifiable by routine light microscopy. A combination of electron microscopy and IHC will demonstrate evidence of squamous, glandular, or neuroendocrine differentiation in as many as 90 percent of cases.",
"   </p>",
"   <p>",
"    Histologically, LCC is characterized by sheets of round to polygonal cells with prominent nucleoli and abundant pale staining cytoplasm without differentiating features (",
"    <a class=\"graphic graphic_picture graphicRef72288 \" href=\"UTD.htm?24/38/25192\">",
"     picture 23",
"    </a>",
"    ). Because LCC represents a diagnosis of exclusion, it is inappropriate to apply the term to small endoscopic biopsies or cytology specimens, both of which have inherent sampling problems. The term NSCLC is more appropriate for cases diagnosed in this way.",
"   </p>",
"   <p>",
"    LCC usually presents as a large peripheral mass with prominent necrosis. The behavior of these tumors parallels that of other poorly differentiated NSCLCs.",
"   </p>",
"   <p>",
"    Several variants are recognized (",
"    <a class=\"graphic graphic_table graphicRef59692 \" href=\"UTD.htm?19/17/19740\">",
"     table 1",
"    </a>",
"    ). Large cell neuroendocrine carcinoma may be particularly important because of its similarities to small cell carcinoma. (See",
"    <a class=\"local\" href=\"#H1176454\">",
"     'Neuroendocrine tumors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Large cell neuroendocrine carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176731\">",
"    <span class=\"h1\">",
"     SARCOMATOID CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomatoid carcinoma represents a heterogeneous group of NSCLCs that contain a component of sarcoma or sarcoma-like elements. In a large Surveillance, Epidemiology, and End Results (SEER) database study, sarcomatoid carcinomas are rare, comprising less than 1 percent of all lung cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/20\">",
"     20",
"    </a>",
"    ]. A histologic diagnosis of sarcomatoid carcinoma was associated with overall worse survival (HR for death 1.60; 95% CI 1.35-2.06).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176738\">",
"    <span class=\"h2\">",
"     Pleomorphic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This designation is used when a non-small carcinoma, such as a squamous carcinoma, is combined with greater than 10 percent of a second component of either giant cells or spindle cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176745\">",
"    <span class=\"h2\">",
"     Spindle cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are tumors comprised only of malignant spindle cells. The diagnosis of \"carcinoma\" in this setting can usually be confirmed by the use of IHC stains for keratin that will decorate at least some tumor cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176752\">",
"    <span class=\"h2\">",
"     Giant cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large bizarre tumor cells are not specific to any one histologic category and can be seen in otherwise typical squamous cell and adenocarcinomas. The term giant cell carcinoma is restricted to those tumors in which bizarre pleomorphic giant cells (greater than 40 microns) comprise at least 10 percent of the neoplastic population (",
"    <a class=\"graphic graphic_picture graphicRef55113 \" href=\"UTD.htm?23/9/23704\">",
"     picture 24",
"    </a>",
"    ). The tumor cells are frequently multinucleated and may contain polymorphonuclear leukocytes in their cytoplasm. Defined in this way, giant cell carcinoma has a very poor prognosis and is distinguished by an unusual propensity to metastasize to the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176759\">",
"    <span class=\"h2\">",
"     Carcinosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This lung malignancy is defined by the presence of a typical carcinoma (squamous or adenocarcinoma) combined with sarcomatous elements (bone, cartilage or skeletal muscle). Typical sarcomatous components include rhabdomyosarcoma, osteosarcoma, and chondrosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176766\">",
"    <span class=\"h2\">",
"     Pulmonary blastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tumors are biphasic malignancies that have an adenocarcinoma component that has the appearance of fetal adenocarcinoma and a stroma that resembles that seen in Wilms tumor. They are usually large at the time of presentation and are highly malignant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176454\">",
"    <span class=\"h1\">",
"     NEUROENDOCRINE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tumor types are grouped based upon shared neuroendocrine features (",
"    <a class=\"graphic graphic_table graphicRef50502 \" href=\"UTD.htm?13/32/13836\">",
"     table 5",
"    </a>",
"    ). These tumors include small cell carcinoma, large cell neuroendocrine carcinoma, typical carcinoid, and atypical carcinoid. In addition, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, a possibly preinvasive epithelial lesion, is included in this category [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the group of pulmonary neuroendocrine tumors, typical and atypical carcinoids share a number of features and are similar to carcinoid lesions arising at other sites. Small cell carcinomas and large cell neuroendocrine carcinomas are characterized clinically by a more aggressive course and pathologically by a much higher mitotic rate (11 or more mitoses per 10 high power fields). Small cell and large cell neuroendocrine tumors are distinguished from each other based upon histopathologic criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Small cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung carcinoma (SCLC) accounts for approximately 15 percent of all bronchogenic carcinomas. SCLC shows a strong correlation with cigarette smoking and is extremely rare in persons who have never smoked. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular studies have identified a number of abnormalities in SCLCs, including in particular deletions in chromosome 3p. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Genetic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the general pathologic features of SCLC have not changed, there has been some alteration in the terminology utilized because of several issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There appears to be no prognostic importance to the historical \"oat",
"      <span class=\"nowrap\">",
"       cell\"/intermediate",
"      </span>",
"      subtype distinction [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/22-24\">",
"       22-24",
"      </a>",
"      ], although on purely morphologic grounds, knowledge of the spectrum of SCLC is critical for the pathologist.",
"     </li>",
"     <li>",
"      SCLCs are heterogeneous. Some are associated with large cells that have similar cytologic features and may even contain small nucleoli. These tumors tend to be as responsive to chemotherapy as are pure SCLCs.",
"     </li>",
"     <li>",
"      About 5 percent of cases of SCLC may also be combined with non-small cell elements, such as squamous carcinoma or adenocarcinoma and still respond at least initially to therapy directed to small cell carcinoma. According to the WHO, such tumors should be subsumed under the \"combined\" rubric, listing both components present (eg, combined small cell and squamous carcinoma). Tumors should be comprised of at least 10 percent of a second component for classification as a combined small cell non small cell carcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SCLC is composed of a pleomorphic population of small cells (with a cell size no larger than the size of three resting lymphocyte nuclei) (",
"    <a class=\"graphic graphic_picture graphicRef81277 \" href=\"UTD.htm?28/58/29609\">",
"     picture 25",
"    </a>",
"    ). These may be round, oval, angulated, and with variable amounts of cytoplasm; the classic \"oat cell\" has virtually no cytoplasm, while the \"intermediate\" subtype may have a small amount of palely eosinophilic cytoplasm. The nuclei are typically hyperchromatic and either have a dispersed \"salt and pepper\" chromatin or a homogeneous dispersed chromatin. The cells are fragile and the tumors are generally extensively necrotic, both of which may contribute to the difficulty in establishing a histologic diagnosis.",
"   </p>",
"   <p>",
"    Although SCLCs are considered part of the larger family of neuroendocrine lung tumors, neuroendocrine characteristics may be difficult to demonstrate in individual cases, even with a combination of electron microscopy and IHC. For that reason, special studies play only a minor role in accurate diagnosis and classification of small cell carcinoma. (See",
"    <a class=\"local\" href=\"#H1176454\">",
"     'Neuroendocrine tumors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Non-small cell neuroendocrine tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Non-small cell neuroendocrine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung tumors with neuroendocrine differentiation share certain morphologic and biochemical characteristics, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of submicroscopic cytoplasmic dense core (neuroendocrine) granules",
"     </li>",
"     <li>",
"      The capacity to synthesize neuropeptides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This group of tumors has been the subject of considerable controversy in the past, resulting in multiple competing and confusing classification schemes. The latest 2004 WHO classification considers neuroendocrine tumors of the lung to represent a spectrum of clinicopathologic entities ranging from hyperplastic neuroendocrine cell lesions (carcinoid tumorlets, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia) to high-grade neuroendocrine tumors (small cell carcinoma [SCLC] and large cell neuroendocrine carcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/21\">",
"     21",
"    </a>",
"    ]. Along this spectrum, typical carcinoid and atypical carcinoid tumors are considered to be low-grade and intermediate-grade neuroendocrine tumors, respectively (",
"    <a class=\"graphic graphic_table graphicRef50502 \" href=\"UTD.htm?13/32/13836\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     DIPNECH and carcinoid tumorlets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and carcinoid tumorlets have been described in a variety of clinical contexts including bronchiectasis, fibrosis and obliterative bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. However, their true nature is uncertain.",
"   </p>",
"   <p>",
"    The 2004 WHO classification applies the term DIPNECH to a proliferation of scattered single pulmonary neuroendocrine cells, nodules, or linear proliferations of these cells confined to bronchial and bronchiolar epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the frequent presence of tumorlets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral carcinoids, it has been proposed that DIPNECH represents a precursor to pulmonary neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/25,29\">",
"     25,29",
"    </a>",
"    ]. However, the risk of developing clinically significant disease from these lesions appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carcinoid tumorlets are typical carcinoid tumors which measure 5 mm or less in greatest dimension. Their clinical significance remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/28\">",
"     28",
"    </a>",
"    ]. Tumorlets have been described in normal lungs, sometimes diagnosed as metastatic disease in the setting of a prior malignancy, in association with peripherally located bronchial carcinoid tumors, and in association with lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/28,30-32\">",
"     28,30-32",
"    </a>",
"    ]. In about one-third of cases, there is a dominant carcinoid tumor present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Typical carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These neoplasms are composed of cytologically bland cells containing regular round to oval nuclei with finely dispersed chromatin and inconspicuous or small nucleoli. The cells are usually polygonal in shape and are arranged in distinct organoid, trabecular, or insular growth patterns with a delicate vascular stroma (",
"    <a class=\"graphic graphic_picture graphicRef81750 graphicRef53833 \" href=\"UTD.htm?33/19/34106\">",
"     picture 26A-B",
"    </a>",
"    ). Mitotic figures are scarce",
"    <span class=\"nowrap\">",
"     (&lt;2/10",
"    </span>",
"    high-powered fields), and necrosis is not seen. Peripherally located tumors differ in that they are often composed of closely packed spindle-shaped cells.",
"   </p>",
"   <p>",
"    Typical carcinoid tumors are classified as low-grade neuroendocrine tumors (",
"    <a class=\"graphic graphic_picture graphicRef50492 \" href=\"UTD.htm?5/4/5192\">",
"     picture 27",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Atypical carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical carcinoid tumors are classified as intermediate grade neuroendocrine tumors in the 2004 WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ]. Pathologic criteria for recognition of atypical carcinoid tumors as delineated by the WHO include the presence of carcinoid morphology and at least one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Necrosis (",
"      <a class=\"graphic graphic_picture graphicRef59297 graphicRef81703 \" href=\"UTD.htm?37/12/38090\">",
"       picture 28A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mitoses (2 to 10 per 10 high power fields)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytologic atypia is also characteristic but is not sufficient for a diagnosis of atypical carcinoid tumor and should be accompanied by the above-named features. There is an inconsistent correlation between \"atypical\" histology in carcinoid tumors and DNA aneuploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/33\">",
"     33",
"    </a>",
"    ]. Although aneuploidy seems to be more common in atypical tumors, abnormal DNA content provides no additional prognostic information.",
"   </p>",
"   <p>",
"    The clinical features and treatment of atypical carcinoid tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neuroendocrine lung tumors described above usually can be diagnosed on the basis of light microscopy alone. Immunohistochemical staining for neuropeptides (eg, neuron specific enolase, chromogranin, synaptophysin, serotonin, bombesin) and electron microscopy can be helpful in difficult cases but are not required for diagnosis. Application of these techniques to NSCLCs will reveal neuroendocrine differentiation in two additional groups of tumors, the large cell neuroendocrine carcinomas and NSCLCs with neuroendocrine differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Large cell neuroendocrine carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term large cell neuroendocrine carcinoma (LCNEC) refers to a group of pulmonary tumors that have a neuroendocrine phenotype by light microscopy, but do not meet the criteria for the three better recognized neuroendocrine tumors (carcinoid, atypical carcinoid, and small cell carcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/34\">",
"     34",
"    </a>",
"    ]. The term \"neuroendocrine carcinoma of intermediate cell type\" was proposed for this group of tumors but was not adopted by the WHO because of the potential for confusion with the intermediate variant of small cell carcinoma. The WHO classification system includes these tumors with poorly-differentiated neuroendocrine carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, LCNEC has an architecture that suggests neuroendocrine differentiation: the cells are arranged in organoid, trabecular, or palisading patterns (",
"    <a class=\"graphic graphic_picture graphicRef50765 graphicRef63311 \" href=\"UTD.htm?33/52/34634\">",
"     picture 29A-B",
"    </a>",
"    ). Necrosis is usually prominent and may be extensive and infarct-like. Evidence of neuroendocrine differentiation is usually demonstrated by immunoreactivity for chromogranin and synaptophysin (",
"    <a class=\"graphic graphic_picture graphicRef70724 graphicRef66047 \" href=\"UTD.htm?26/59/27578\">",
"     picture 30A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The tumor cells tend to be polygonal, with a low nucleus:cytoplasm ratio. The cells are generally larger than those of small cell carcinoma and, by definition, have a cell size greater than the diameter of three resting lymphocytes. They have abundant, often eosinophilic, cytoplasm. The mitotic rate is significantly higher than that seen in atypical carcinoids and may average up to",
"    <span class=\"nowrap\">",
"     66/10",
"    </span>",
"    hpf (range, 22 to 138). By the WHO criteria, their mitotic rate should be",
"    <span class=\"nowrap\">",
"     &gt;10/10",
"    </span>",
"    hpf. The nuclear chromatin tends to be coarse and granular, and nucleoli are frequently prominent.",
"   </p>",
"   <p>",
"    These tumors are distinguished from other NSCLCs that may have immunohistochemical or electron microscopic evidence of neuroendocrine differentiation but do not appear \"neuroendocrine\" by light microscopy (see",
"    <a class=\"local\" href=\"#H25\">",
"     'NSCLC with neuroendocrine differentiation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The clinical presentation and natural history of LCNEC appears to be intermediate between that of SCLC and other large cell carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The largest reported series identified 1211 patients from the Surveillance, Epidemiology and End Results (SEER) database identified over an eight-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/36\">",
"     36",
"    </a>",
"    ]. Of these, 18 percent were stage I at presentation and 7 percent had stage II disease. For those managed with surgery, overall and lung-cancer specific survival was significantly better than for patients with SCLC. The limitation of the SEER database is that specimens are not reviewed by pathologists with expertise in lung malignancy.",
"   </p>",
"   <p>",
"    Although there are no prospectively controlled data, surgical resection when feasible, followed by combination chemotherapy similar to that employed for SCLC, would appear to offer the best chance for improved survival in patients with early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. For patients with stage III and IV disease, chemotherapy utilizes platinum-based regimens similar to those for SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/39\">",
"     39",
"    </a>",
"    ]. The presence of an activating mutation in EGFR has been described in one case, in which subsequent treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    resulted in a clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     NSCLC with neuroendocrine differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of lung carcinomas of conventional histologic type (ie, squamous cell carcinoma, adenocarcinoma, large cell carcinoma) have immunophenotypic or ultrastructural evidence of neuroendocrine differentiation; these tumors are generically termed NSCLCs with neuroendocrine differentiation. They account for 10 to 40 percent of NSCLCs, and the significance of neuroendocrine features is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/34\">",
"     34",
"    </a>",
"    ]. While some investigators have reported a more aggressive course [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/41\">",
"     41",
"    </a>",
"    ], others have shown either no difference in survival or improved survival when compared to similar stage tumors that lack neuroendocrine differentiation, particularly when they are treated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22201/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung malignancies should be classified according to the World Health Organization (WHO) system (",
"      <a class=\"graphic graphic_table graphicRef50502 \" href=\"UTD.htm?13/32/13836\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification schemes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A new classification system has been recommended for adenocarcinoma by an international multidisciplinary committee, but this has not yet been adopted by the WHO. (See",
"      <a class=\"local\" href=\"#H1177702\">",
"       '2011 IASLC/ATS/ERS classification of adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common histologic category is adenocarcinoma. Most of the remaining cases are squamous cell, small cell, or large cell carcinomas. Various rare types of lung cancer make up a small minority of cases. (See relevant sections above).",
"     </li>",
"     <li>",
"      Classification of lung cancers is necessary for appropriate treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"       \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: World Health Organization classification of tumours, Travis, WD, Brambilla, E, Muller-Hermlink, HK, Harris, CC (Eds), IARC Press, Lyon 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/3\">",
"      Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/4\">",
"      Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010; 5:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/5\">",
"      Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010; 5:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/6\">",
"      Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/7\">",
"      Janssen-Heijnen ML, Coebergh JW, Klinkhamer PJ, et al. Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung? Epidemiology 2001; 12:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/8\">",
"      Kish JK, Ro JY, Ayala AG, McMurtrey MJ. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol 1989; 20:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/9\">",
"      Moran CA. Mucin-rich tumors of the lung. Adv Anat Pathol 1995; 2:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/10\">",
"      Ou SH, Ziogas A, Zell JA. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol 2010; 5:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/11\">",
"      Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/12\">",
"      Silver SA, Askin FB. True papillary carcinoma of the lung: a distinct clinicopathologic entity. Am J Surg Pathol 1997; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/13\">",
"      Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/14\">",
"      Nakatani Y, Dickersin GR, Mark EJ. Pulmonary endodermal tumor resembling fetal lung: a clinicopathologic study of five cases with immunohistochemical and ultrastructural characterization. Hum Pathol 1990; 21:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/15\">",
"      Yousem SA, Wick MR, Randhawa P, Manivel JC. Pulmonary blastoma. An immunohistochemical analysis with comparison with fetal lung in its pseudoglandular stage. Am J Clin Pathol 1990; 93:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/16\">",
"      Roggli VL, Vollmer RT, Greenberg SD, et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985; 16:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/17\">",
"      Cooke DT, Nguyen DV, Yang Y, et al. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010; 90:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/18\">",
"      Filosso PL, Ruffini E, Asioli S, et al. Adenosquamous lung carcinomas: a histologic subtype with poor prognosis. Lung Cancer 2011; 74:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/19\">",
"      Dulmet-Brender E, Jaubert F, Huchon G. Exophytic endobronchial epidermoid carcinoma. Cancer 1986; 57:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/20\">",
"      Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery 2012; 152:397.",
"     </a>",
"    </li>",
"    <li>",
"     Travis, WD.. The concept of pulmonary neuroendocrine tumours.. In: Pathology &amp; Genetics: Tumours of the Lung, Pleura, Thymus, and Heart., Travis, WD, Brambilla, E, Muller-Hermelink, HK, Harris, CC. (Eds), IARC Press, Lyon 2004. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/22\">",
"      Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988; 62:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/23\">",
"      Bepler G, Neumann K, Holle R, et al. Clinical relevance of histologic subtyping in small cell lung cancer. Cancer 1989; 64:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/24\">",
"      Aisner SC, Finkelstein DM, Ettinger DS, et al. The clinical significance of variant-morphology small-cell carcinoma of the lung. J Clin Oncol 1990; 8:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/25\">",
"      Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 2007; 62:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/26\">",
"      Armas OA, White DA, Erlandson RA, Rosai J. Diffuse idiopathic pulmonary neuroendocrine cell proliferation presenting as interstitial lung disease. Am J Surg Pathol 1995; 19:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/27\">",
"      Aguayo SM, Miller YE, Waldron JA Jr, et al. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 1992; 327:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/28\">",
"      Aubry MC, Thomas CF Jr, Jett JR, et al. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest 2007; 131:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/29\">",
"      Gosney JR. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors. Chest 2004; 125:108S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/30\">",
"      Bonikos DS, Archibald R, Bensch KG. On the origin of the so-called tumorlets of the lung. Hum Pathol 1976; 7:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/31\">",
"      D'Agati VD, Perzin KH. Carcinoid tumorlets of the lung with metastasis to a peribronchial lymph node. Report of a case and review of the literature. Cancer 1985; 55:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/32\">",
"      Darvishian F, Ginsberg MS, Klimstra DS, Brogi E. Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer. Hum Pathol 2006; 37:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/33\">",
"      el-Naggar AK, Ballance W, Karim FW, et al. Typical and atypical bronchopulmonary carcinoids. A clinicopathologic and flow cytometric study. Am J Clin Pathol 1991; 95:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/34\">",
"      Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/35\">",
"      Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/36\">",
"      Varlotto JM, Medford-Davis LN, Recht A, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol 2011; 6:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/37\">",
"      Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005; 23:8774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/38\">",
"      Veronesi G, Morandi U, Alloisio M, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006; 53:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/39\">",
"      Yamazaki S, Sekine I, Matsuno Y, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005; 49:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/40\">",
"      De Pas TM, Giovannini M, Manzotti M, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol 2011; 29:e819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/41\">",
"      Gonz&aacute;lez-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, et al. Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer 2007; 110:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22201/abstract/42\">",
"      Schleusener JT, Tazelaar HD, Jung SH, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996; 77:1284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4603 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22201=[""].join("\n");
var outline_f21_43_22201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION SCHEMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1177650\">",
"      2004 WHO classification of adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1177702\">",
"      2011 IASLC/ATS/ERS classification of adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H979379364\">",
"      ADENOSQUAMOUS CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1177018\">",
"      SQUAMOUS CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LARGE CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1176731\">",
"      SARCOMATOID CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1176738\">",
"      Pleomorphic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1176745\">",
"      Spindle cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1176752\">",
"      Giant cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1176759\">",
"      Carcinosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1176766\">",
"      Pulmonary blastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1176454\">",
"      NEUROENDOCRINE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Small cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Non-small cell neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - DIPNECH and carcinoid tumorlets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Typical carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Atypical carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Large cell neuroendocrine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - NSCLC with neuroendocrine differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4603\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4603|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/0/2050\" title=\"diagnostic image 1\">",
"      CT of preinvasive lesion - AAH or AIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/59/16307\" title=\"diagnostic image 2\">",
"      CT of a peripheral 2 cm nonmucinous adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/9/42128\" title=\"diagnostic image 3\">",
"      CT of nonmucinous minimally invasive adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/3/11313\" title=\"diagnostic image 4\">",
"      CT of mucinous adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4603|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/53/12120\" title=\"picture 1\">",
"      Adeno CA lung Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/10/28839\" title=\"picture 2\">",
"      Adeno CA lung Light II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/28/12743\" title=\"picture 3\">",
"      Intracytoplasmic mucin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/21/44375\" title=\"picture 4\">",
"      Cystic mucinous CA lung Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/11/9392\" title=\"picture 5\">",
"      Mucinous carcinoma lung gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/1/18457\" title=\"picture 6\">",
"      Fetal adenoca lung low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/61/20439\" title=\"picture 7\">",
"      Atypical adenomatous hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/34/14889\" title=\"picture 8\">",
"      Nonmucinous adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/8/2185\" title=\"picture 9\">",
"      Mucinous adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/47/33529\" title=\"picture 10\">",
"      Nonmucinous minimally invasive adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/50/40743\" title=\"picture 11\">",
"      Mucinous minimally invasive adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/49/40730\" title=\"picture 12\">",
"      Major histologic patterns of invasive adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/10/9383\" title=\"picture 13\">",
"      Invasive mucinous adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/43/18106\" title=\"picture 14\">",
"      Adenocarcinoma variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/26/31145\" title=\"picture 15\">",
"      Adenocarcinoma in small biopsy and cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/35/38453\" title=\"picture 16\">",
"      Squamous CA keratin Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/29/15831\" title=\"picture 17\">",
"      Keratinization lung CA Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/7/8305\" title=\"picture 18\">",
"      Squamous CA lung cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/1/38933\" title=\"picture 19\">",
"      Desmosomes squamous CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/10/2211\" title=\"picture 20\">",
"      Central squamous CA gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/22/42340\" title=\"picture 21\">",
"      Squamous CA cavitation Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/36/20033\" title=\"picture 22\">",
"      Exophytic squamous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/38/25192\" title=\"picture 23\">",
"      Large cell lung CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/9/23704\" title=\"picture 24\">",
"      Giant cell lung ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/58/29609\" title=\"picture 25\">",
"      Pathology of SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/44/36552\" title=\"picture 26A\">",
"      Carcinoid lung low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/16/6407\" title=\"picture 26B\">",
"      Oncocytic oxyphilic carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/4/5192\" title=\"picture 27\">",
"      Typical carcinoid organoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/11/11448\" title=\"picture 28A\">",
"      Atypical carcinoid necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/56/3977\" title=\"picture 28B\">",
"      Atypical carcinoid lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/61/13272\" title=\"picture 29A\">",
"      Neuroendocrine high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41559\" title=\"picture 29B\">",
"      Neuroendocrine low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/34/44582\" title=\"picture 30A\">",
"      Neuroendocrine chromogranin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/28/36295\" title=\"picture 30B\">",
"      Neuroendocrine carcinoma stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4603|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/17/19740\" title=\"table 1\">",
"      WHO classification lung cancer 2004",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/25/14748\" title=\"table 2\">",
"      IASLC ATS ERS classification of lung adenocarcinoma in resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/11/31933\" title=\"table 3\">",
"      Proposed IASLC ATS ERS classification small biopsies cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/29/15837\" title=\"table 4\">",
"      Adenocarcinoma histologic molecular radiologic subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/32/13836\" title=\"table 5\">",
"      WHO neuroendo tum lung 2004",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22202="Systemic treatment for metastatic breast cancer: Molecular targeted therapy";
var content_f21_43_22202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/43/22202/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22202/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/43/22202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22202/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/43/22202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/43/22202/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/43/22202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H111525243\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although metastatic breast cancer is unlikely to be cured, there is a wide range of treatment options available, allowing for the selection of a tailored treatment strategy for individual patients. While some studies suggest there has been little impact on survival among patients with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/1\">",
"     1",
"    </a>",
"    ], other studies have shown that survival has improved, coincident with the expanded options to treat this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Molecular therapies that specifically target pathways, such as those involving the estrogen receptor or the human epidermal growth factor 2 (HER2) receptor, have broadened the therapeutic options for metastatic breast cancer. Attempts to target other pathways, such as those involving mTOR and angiogenesis, are underway but are less established. Molecular targeted therapies will be discussed here with the exception of endocrine therapy for hormone receptor-positive metastatic breast cancer, which is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with metastatic breast cancer receive systemic medical therapy, consisting of chemotherapy, endocrine therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecular targeted therapies, and supportive care measures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The efficacy and dosing of combination chemotherapy regimens, including combination treatment of chemotherapy with molecular targeted therapies, are presented here. General principles of management of metastatic breast cancer, selection of chemotherapy regimen, and use of single agent and combination chemotherapy, endocrine therapy, and supportive care are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111523989\">",
"    <span class=\"h1\">",
"     HER2-DIRECTED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with HER2-positive metastatic breast cancer, we administer treatment that includes a HER2-directed agent in the first-line setting; we also continue HER2-directed treatment upon disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 20 percent of breast cancers overexpress HER2, a transmembrane glycoprotein receptor with tyrosine kinase activity. Historically, overexpression of this receptor was associated with increased disease recurrence and an overall worse prognosis. However, HER2-directed agents have improved the survival outcomes for these patients, thereby altering the natural history of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HER2-positivity is characterized as either 3+ immunohistochemical staining (IHC) for the HER2 protein or evidence of HER2 gene amplification by fluorescence in situ hybridization (FISH &gt;2.0). Both of these criteria strongly predict sensitivity to HER2-targeted agents and are used to select patients for these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In contrast, the lack of HER2 overexpression (HER2-negativity) identifies patients who do not appear to benefit from these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The assessment of HER2 status, selection of patients for HER2-directed treatment, and HER2 status discordance between the primary tumor and metastases are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226705306\">",
"    <span class=\"h2\">",
"     Treatment selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four HER2-directed agents are available for use in the treatment of HER2-positive breast cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      : Trastuzumab is a monoclonal antibody that binds the extracellular domain of HER2. (See",
"      <a class=\"local\" href=\"#H111523996\">",
"       'Trastuzumab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"       Ado-trastuzumab emtansine",
"      </a>",
"      (formerly known as T-DM1): T-DM1 is an antibody-drug conjugate composed of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , a thioether linker, and the antimicrotubule agent, mertansine. (See",
"      <a class=\"local\" href=\"#H720673240\">",
"       'Ado-trastuzumab emtansine'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      : Lapatinib is a tyrosine kinase inhibitor against EGFR1 and HER2 that results in inhibition of signaling pathways downstream of HER2. (See",
"      <a class=\"local\" href=\"#H726455386\">",
"       'Lapatinib'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       Pertuzumab",
"      </a>",
"      : Pertuzumab binds the extracellular dimerization domain of HER2 and prevents it from binding to itself or to other members of the epidermal growth factor receptor (EGFR) family. It is administered in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      rather than as a single agent in the treatment of HER2-positive breast cancer. (See",
"      <a class=\"local\" href=\"#H104779482\">",
"       'Pertuzumab'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultimately, the treatment of HER2-positive patients with metastatic breast cancer should be guided by patient preferences. Examples of this include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preferences about treatment schedules: Patients may require treatment every three or four weeks (ie, due to distance from the infusion center), in which case the use of a regimen administered every three weeks (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      or T-DM1) might be preferred.",
"     </li>",
"     <li>",
"      Pre-existing toxicities: For patients previously treated with systemic therapy, residual toxicities should be considered in the choice of a subsequent regimen. For example, patients with residual neuropathy may not be candidates for further treatment with taxanes; options include the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      or combined HER2-directed therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      plus trastuzumab).",
"     </li>",
"     <li>",
"      Preferences regarding treatment delivery: Some patients may prefer oral rather than intravenous therapy. For these patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      represents an orally available option. (See",
"      <a class=\"local\" href=\"#H726455386\">",
"       'Lapatinib'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H597117472\">",
"    <span class=\"h2\">",
"     Approach to patients previously treated with adjuvant trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given its proven effectiveness in the adjuvant setting, most patients with HER2-positive breast cancer likely received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    as part of their initial (adjuvant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neoadjuvant) treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients who develop metastatic breast cancer, we continue HER2-directed treatment. Although limited, the available data support this approach. One study reviewed the outcomes of 26 patients who relapsed after receiving at least one dose of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for early HER2-expressing breast cancer (15 of whom received trastuzumab in the setting of metastatic breast cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/16\">",
"     16",
"    </a>",
"    ]. Although there was no difference in the time to tumor progression between the groups, overall survival was longer among those who were re-treated with trastuzumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H803307141\">",
"    <span class=\"h3\">",
"     The treatment-free interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment-free interval is defined as the time between the end of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    treatment to disease progression. In the US, the issue of a treatment-free interval is considered in drug approvals by the Food and Drug Administration (FDA). For example, recurrence within six months of trastuzumab is part of the FDA approved indication for T-DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/17\">",
"     17",
"    </a>",
"    ]. While some experts adopt a treatment-free interval of 12 months to determine which HER2-directed treatment to administer, others utilize the shorter interval (eg, six months) used in US drug approvals.",
"   </p>",
"   <p>",
"    Whether the treatment-free interval predicts the activity of subsequent HER2-directed treatment is not clear. In the study discussed earlier, 13 of 26 patients relapsed after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was completed (at a median of 21 months) while the rest relapsed while receiving adjuvant trastuzumab; approximately half in each group received trastuzumab for metastatic breast cancer. Overall survival (OS) was longer for those who relapsed following completion of adjuvant trastuzumab compared to those who relapsed during treatment (38 versus 17 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/16\">",
"     16",
"    </a>",
"    ]. These results suggest that a treatment free interval may predict response to subsequent trastuzumab treatment and perhaps, prognosis. However, whether 6, 12, or another treatment-free interval should be used has not been further evaluated.",
"   </p>",
"   <p>",
"    In view of the lack of high quality data regarding the issue of a treatment free interval, we use a cut-off of 6 rather than 12 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who relapse six months or longer from prior adjuvant treatment, we utilize",
"      <strong>",
"       first-line",
"      </strong>",
"      HER2-directed treatment. In addition, patients who develop metastatic breast cancer and were not treated with adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      should receive first-line HER2-directed therapy.",
"     </li>",
"     <li>",
"      For patients who relapse during adjuvant treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      or within six months of prior HER2-directed treatment, we utilize",
"      <strong>",
"       second- or later-line",
"      </strong>",
"      HER2-directed treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The options for treatment in both of these settings are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111523996\">",
"    <span class=\"h2\">",
"     Trastuzumab",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210541765\">",
"    <span class=\"h3\">",
"     First-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is appropriate for patients who relapse six months or longer following adjuvant trastuzumab. In addition, patients who were not previously treated with HER2-directed therapy at the time of initial diagnosis should receive first-line treatment with trastuzumab.",
"   </p>",
"   <p>",
"    For patients previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in the adjuvant setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We administer HER2-directed therapy plus endocrine therapy for patients with hormone receptor- and HER2-positive metastatic breast cancer that is not rapidly progressive, symptomatic, or without findings of diffuse visceral involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link&amp;anchor=H19266990#H19266990\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'HER2-positive breast cancer'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      We administer chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for all other patients. Our preferred combination consists of trastuzumab and a taxane. (See",
"      <a class=\"local\" href=\"#H28338387\">",
"       'Trastuzumab combinations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      monotherapy is a reasonable alternative option in the first-line setting, particularly in patients with limited",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asymptomatic metastatic breast cancer. (See",
"      <a class=\"local\" href=\"#H1143301128\">",
"       'Trastuzumab monotherapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who were not previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in the adjuvant setting, we prefer treatment with trastuzumab plus chemotherapy. However, these patients have two additional options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      (ie, pertuzumab plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H104779482\">",
"       'Pertuzumab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Single agent T-DM1 (See",
"      <a class=\"local\" href=\"#H720673240\">",
"       'Ado-trastuzumab emtansine'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28338387\">",
"    <span class=\"h4\">",
"     Trastuzumab combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Where it has been studied, treatment with chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    increases the rates of response, progression-free survival, and overall survival compared to treatment with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. However, there have been limited trials comparing the various options of chemotherapy when administered with trastuzumab. In the absence of a preferred regimen, many oncologists consider the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus trastuzumab to represent the best first-line chemotherapy option for HER2-positive metastatic breast cancer based on activity and limited toxicity of this combination [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was shown in a pivotal phase III trial in which patients were randomly assigned to chemotherapy with or without trastuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients who were anthracycline-naive were treated with an anthracycline-based regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) while those with prior anthracycline exposure were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . Compared to chemotherapy alone, the addition of trastuzumab significantly prolonged time to disease progression (7 versus 5 months) and OS (25 versus 20 months). Although the combination of anthracycline and trastuzumab was highly effective, it resulted in a high rate of cardiomyopathy. Therefore, this combination is not generally administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link&amp;anchor=H95247583#H95247583\">",
"     \"Cardiotoxicity of trastuzumab\", section on 'Acceptable concurrent treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical chemotherapy combinations include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for two weeks repeated every 21 days) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 21 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/14,18\">",
"       14,18",
"      </a>",
"      ]",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"      (1250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 days followed by a seven-day rest) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/19\">",
"       19",
"      </a>",
"      ]",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      (25 to 35",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      (1200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8 of a 21-day cycle) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      (See",
"      <a class=\"local\" href=\"#H104779482\">",
"       'Pertuzumab'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143301234\">",
"    <span class=\"h5\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who subsequently have a good response to chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , it is not clear if chemotherapy should be continued once there has been a maximal response (eg, complete response or prolonged disease stabilization through two or more treatment cycles), until disease progression, or until the patients experiences intolerable toxicity warranting treatment discontinuation.",
"   </p>",
"   <p>",
"    In the absence of high quality data, discontinuing chemotherapy for patients who appear to have achieved a maximal benefit from combination therapy is reasonable, especially if treatment is becoming more difficult (eg, due to toxicities). In this case, we continue single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , although there is a similar lack of data on the optimal duration of trastuzumab treatment in this context. In the absence of high quality data, we tend to continue trastuzumab in this setting as long as there are no or limited toxicities and the patient wishes to proceed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143300768\">",
"    <span class=\"h5\">",
"     Trastuzumab plus multiagent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not administer combination chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for HER2-positive metastatic breast cancer. The results from randomized trials do not consistently demonstrate this approach improves outcomes in this population. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III trial enrolled 196 women who were randomly assigned to treatment with which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/23\">",
"       23",
"      </a>",
"      ]. The addition of carboplatin resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A higher overall response rate (ORR, 52 versus 36 percent, p=0.04)",
"     </li>",
"     <li>",
"      Increase in the median progression-free survival (PFS, 11 versus 7 months, HR 0.66, 95% CI 0.59-0.73).",
"     </li>",
"     <li>",
"      A trend towards improved OS (36 versus 32 months, HR 0.90, 95% CI 0.88-0.92)",
"     </li>",
"     <li>",
"      A higher incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic toxicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A separate phase III trial enrolled 263 women who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/24\">",
"       24",
"      </a>",
"      ]. Unlike the prior trial, the addition of carboplatin did not improve ORR, PFS, or OS. It was also associated with more episodes of serious toxicity, including neutropenia-related complications, thrombocytopenia, and diarrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus multiagent chemotherapy, there is evidence that combined HER2-blockade with chemotherapy may be more effective than trastuzumab plus single agent chemotherapy. An example of this strategy is the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    plus trastuzumab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , which is discussed below. (See",
"    <a class=\"local\" href=\"#H104779482\">",
"     'Pertuzumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143300749\">",
"    <span class=\"h5\">",
"     Combination versus sequential therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the data are limited, they support treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    concomitantly with single-agent chemotherapy rather than as sequential monotherapy (ie, trastuzumab followed by chemotherapy on disease progression). This was shown in a",
"   </p>",
"   <p>",
"    phase II trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (combination therapy) versus trastuzumab followed by docetaxel alone at progression (sequential therapy) in 101 patients with previously untreated HER2-positive metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/25\">",
"     25",
"    </a>",
"    ]. The main results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall response rate (ORR) was higher using combination rather than sequential treatment (79 vs. 53 percent, p=0.016).",
"     </li>",
"     <li>",
"      Combination and sequential treatment resulted in similar progression free survival (PFS, median, 9 versus 10 months, respectively).",
"     </li>",
"     <li>",
"      Overall survival (OS) was longer with combination therapy (31 versus 20 months), although this difference was not statistically significant (p=0.11).",
"     </li>",
"     <li>",
"      The incidence and severity of neuropathy was higher in patients treated with combination therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143301128\">",
"    <span class=\"h4\">",
"     Trastuzumab monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is a reasonable option for some patients with metastatic breast cancer, particularly if there is limited metastatic disease (eg, bone only metastases)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asymptomatic disease present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/11,26-28\">",
"     11,26-28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The benefit of single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was shown in 114 patients with newly diagnosed metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/27\">",
"     27",
"    </a>",
"    ]. The objective response rate was 26 percent, and for assessable patients with 3+ HER2-overexpression by immunohistochemistry (IHC), it was 35 percent. Of 30 patients with an objective response, 17 (57 percent) were progression-free survival for at least 12 months.",
"   </p>",
"   <p>",
"    In our practice, we use it in patients with clinically less aggressive metastatic breast cancer (ie, bone only or limited metastatic disease). However, for patients with more aggressive (eg, visceral metastatic disease with evidence of end-organ dysfunction) or symptomatic disease, we prefer a combination regimen. (See",
"    <a class=\"local\" href=\"#H28338387\">",
"     'Trastuzumab combinations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111525572\">",
"    <span class=\"h3\">",
"     Second or later line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data support the continuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for patients who experience disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/25,29\">",
"     25,29",
"    </a>",
"    ]. However, subsequent trastuzumab-based treatment has not been extensively compared against other alternatives, such as T-DM1,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    , or combined HER2-directed treatment with trastuzumab plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    . Therefore, all of these should be considered reasonable alternative options. (See",
"    <a class=\"local\" href=\"#H720673240\">",
"     'Ado-trastuzumab emtansine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H726455386\">",
"     'Lapatinib'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H726453560\">",
"     'Second-line setting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The continuation of second-line",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was evaluated in a trial that included 156 patients who had progressed on trastuzumab monotherapy and were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without trastuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/29\">",
"     29",
"    </a>",
"    ]. Compared to capecitabine alone, the addition of trastuzumab was associated with a significantly longer median time to progression (TTP, median 8 versus 6 months) and an improvement in overall survival (26 versus 20 months), though the latter was not significant. In addition, continuation of trastuzumab was not associated with increased toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111525586\">",
"    <span class=\"h3\">",
"     Trastuzumab dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    may be dosed every three weeks (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose and 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks) or weekly (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose with 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    weekly thereafter), although these schedules have not been directly compared in a clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210542579\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;While treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is generally well tolerated, it is complicated by an increased risk of cardiotoxicity, mainly an asymptomatic decline in left ventricular ejection fraction and uncommonly, heart failure. Caution must be used in prescribing trastuzumab in patients who have previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or have evidence of cardiac dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H720673240\">",
"    <span class=\"h2\">",
"     Ado-trastuzumab emtansine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"     Ado-trastuzumab emtansine",
"    </a>",
"    (formerly known as T-DM1) is an antibody-drug conjugate composed of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , a thioether linker, and a derivative of the antimitotic agent, maytansine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/31\">",
"     31",
"    </a>",
"    ]. In February 2013, T-DM1 was approved by the US FDA for patients who progress during or within six months of adjuvant trastuzumab and those patients who progress following a trastuzumab-based regimen for metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FDA approval was based on the phase III EMILIA trial, which enrolled 978 patients with HER2-positive metastatic breast cancer who were randomly assigned to treatment with T-DM1 (3.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    orally twice a day, days 1 to 14) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    (1250 mg orally daily) with each regimen repeated every three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/32\">",
"     32",
"    </a>",
"    ]. With a median duration of follow-up of 19 months, T-DM1 resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the risk of disease progression compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      (median PFS 10 versus 6 months, respectively, HR 0.65, 95% CI 0.55-0.77).",
"     </li>",
"     <li>",
"      A reduction in mortality compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      (median OS, 31 versus 25 months, HR 0.68, 95% CI 0.55-0.85).",
"     </li>",
"     <li>",
"      A clinically significant improvement in the ORR (44 versus 31 percent).",
"     </li>",
"     <li>",
"      A lower rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity overall (41 versus 57 percent), including diarrhea (2 versus 21 percent), palmar plantar erythrodysesthesia (0 versus 16 percent), and vomiting (0.8 versus 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common serious toxicity associated with T-DM1 was thrombocytopenia (13 versus 0.2 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    ). The incidence of LVEF decline to less than 50 percent was low (2 percent in each arm).",
"   </p>",
"   <p>",
"    Based on these results, we prefer T-DM1 rather than other HER2-directed therapies for patients who progress following treatment with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -based combination regimen. If it is not available, alternatives include other HER2-directed agents (ie, trastuzumab or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    ) in combination with chemotherapy, or combined HER2-blockade (trastuzumab plus either lapatinib or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H111523996\">",
"     'Trastuzumab'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H726455386\">",
"     'Lapatinib'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H104779482\">",
"     'Pertuzumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H720673490\">",
"    <span class=\"h3\">",
"     First-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although T-DM1 has been approved for patients who progressed after treatment with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -based combination regimen, there are data to support its use as a first-line treatment.",
"   </p>",
"   <p>",
"    T-DM1 was evaluated in 137 patients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or T-DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/33\">",
"     33",
"    </a>",
"    ]. Of note, the majority of patients (73 and 82 percent, respectively) had not been previously treated with trastuzumab in the neoadjuvant or adjuvant setting. Compared to trastuzumab plus docetaxel, T-DM1 resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longer median PFS (14 versus 9 months, HR 0.59, 95% CI 0.36-0.97).",
"     </li>",
"     <li>",
"      A higher ORR (64 versus 58 percent).",
"     </li>",
"     <li>",
"      Less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events, including neutropenia (6 versus 62 percent), febrile neutropenia (0 versus 24 percent), and epistaxis (1 versus 5 percent).",
"     </li>",
"     <li>",
"      A higher incidence of serious pneumonia (6 versus 0 percent) and increased liver transaminases (AST, 9 versus 0 percent; ALT, 10 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of treatment on overall survival has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H726455386\">",
"    <span class=\"h2\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    is a small molecule dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1; HER1) and HER2 (ErbB2) that, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , has demonstrated a significant improvement in overall survival when added to chemotherapy in the treatment of HER2-positive metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210541060\">",
"    <span class=\"h3\">",
"     First-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    plus chemotherapy is indicated following disease progression in women previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . However, it has not been compared with other HER2-directed agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    , trastuzumab) in this setting. The additional option of lapatinib in combination with endocrine therapy for the treatment of postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link&amp;anchor=H1056069971#H1056069971\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'Postmenopausal women'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H720673013\">",
"     'Lapatinib plus capecitabine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    in this setting was shown in a trial that included 86 patients with HER2-positive metastatic breast cancer who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    with or without lapatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/34\">",
"     34",
"    </a>",
"    ]. Compared to paclitaxel alone, incorporation of lapatinib significantly improved the ORR (63 versus 38 percent), time to progression (36 versus 25 weeks), and event-free survival. However, as reported, there was no difference in overall survival seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210541067\">",
"    <span class=\"h3\">",
"     Second or later line after trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    is most commonly used following disease progression on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . In this setting, lapatinib can be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or with trastuzumab. These data are reviewed below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H720673013\">",
"    <span class=\"h4\">",
"     Lapatinib plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is a reasonable option for patients who progressed following a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -containing regimen. However, a phase III trial showed that this combination resulted in a lower survival benefit compared to T-DM1. Despite this, it remains a reasonable option for previously treated patients, particularly if T-DM1 is not available. (See",
"    <a class=\"local\" href=\"#H720673240\">",
"     'Ado-trastuzumab emtansine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    was shown in a phase III trial of 399 patients with progressive, HER2-overexpressing metastatic breast cancer who were previously treated with an anthracycline, a taxane, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Patients were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without lapatinib. Compared to single agent capecitabine, combination therapy resulted in a significant benefit in time to progression (median 6 versus 4 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/35\">",
"     35",
"    </a>",
"    ]. At final analysis, combined therapy resulted improved overall survival (75 versus 65 weeks), although this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    As discussed above, a subsequent study comparing the antibody-drug conjugate T-DM1 to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in women previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus a taxane showed that T-DM1 resulted in improved survival outcomes. Therefore, in the setting of disease progression on trastuzumab-based adjuvant therapy (or within six months of treatment) or prior treatment with trastuzumab plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , we prefer T-DM1. (See",
"    <a class=\"local\" href=\"#H720673240\">",
"     'Ado-trastuzumab emtansine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210541131\">",
"    <span class=\"h4\">",
"     Lapatinib plus trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is also an option for patients with HER2-positive metastatic breast cancer whose disease has progressed on trastuzumab. Potential synergy with lapatinib plus trastuzumab was shown in a phase III trial of 296 patients with metastatic breast cancer and disease progression following one or more prior trastuzumab-containing regimens who were randomly assigned to treatment with lapatinib alone or in combination with trastuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Compared to lapatinib alone, the combination of lapatinib and trastuzumab resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in PFS (HR 0.74, 95% CI 0.58-0.94; median, 11 versus 8 weeks)",
"     </li>",
"     <li>",
"      An improvement in OS (HR 0.74, 95% CI 0.57-0.97; median, 14 versus 10 months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of 148 patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    monotherapy arm, 77 patients crossed over to combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/39\">",
"     39",
"    </a>",
"    ]. With exclusion of the patients who crossed over from the analysis, a more pronounced benefit in OS was seen, favoring combination therapy (HR 0.65, 95% CI 0.46-0.94; median, 14 versus 8 months). These data further support the concept of continuous HER2-directed treatment even after a patient has progressed on a prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -containing regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111525688\">",
"    <span class=\"h3\">",
"     Lapatinib dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose adjustments may be needed for concomitant CYP3A4",
"    <span class=\"nowrap\">",
"     inhibitors/inducers,",
"    </span>",
"    severe preexisting hepatic impairment, and toxicity, including gastrointestinal, cardiac, and pulmonary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is controversy as to whether the drug should be taken with a meal (particularly a high-fat meal which increases bioavailability and could reduce the amount of drug needed, as well as the cost of therapy) or in the fasting state [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. We follow the recommendation of the FDA-approved package insert to administer drug in the fasting state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210541101\">",
"    <span class=\"h3\">",
"     Toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    are diarrhea, acneiform skin rash, nausea, and pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. There appears to be no correlation between the presence of skin rash and antitumor efficacy, an association that has been seen with other drugs targeting the EGFR. Congestive heart failure, interstitial lung",
"    <span class=\"nowrap\">",
"     disease/pneumonitis,",
"    </span>",
"    and hepatotoxicity have been observed in a small number of patients during therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627738343\">",
"    <span class=\"h3\">",
"     Progression following lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to guide the treatment of patients who progress after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    . However, some data suggest that re-treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is effective.",
"   </p>",
"   <p>",
"    In a retrospective study of 69 patients treated across nine Italian institutions,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was re-started after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    progression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/44\">",
"     44",
"    </a>",
"    ]. In 65 of these patients, trastuzumab was combined with chemotherapy. The overall response rate was 31 percent with a median duration of response of eight months. The median progression free and overall survival was 5 and 15 months, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104779482\">",
"    <span class=\"h2\">",
"     Pertuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     Pertuzumab",
"    </a>",
"    is a monoclonal antibody that binds sub-domain II of the HER2 extracellular domain and prevents HER2 homo- and heterodimerization with other HER-family receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. While initial studies showed limited activity for patients with HER2-negative metastatic breast cancer, subsequent studies have shown a benefit when it is combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    among patients with HER2-positive disease who had progressed on prior trastuzumab treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104779603\">",
"    <span class=\"h3\">",
"     First-line treatment with trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     Pertuzumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    is an active regimen for patients with untreated HER2-positive metastatic breast cancer. In June 2012, it received approval for this indication by the Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    in combination with chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was shown in a phase III trial of 808 patients with HER2-positive metastatic breast cancer; approximately 90 percent of these patients had not received prior HER2-directed therapy. Patients were randomly assigned to treatment with trastuzumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose then 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV) with randomization to pertuzumab versus placebo (840 mg loading dose then 420 mg) given on day 1 of a 21 day cycle and continued until disease progression or intolerable side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/49\">",
"     49",
"    </a>",
"    ]. Compared to placebo, the addition of pertuzumab resulted in the following at a median follow-up of 19 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant improvement in median progression free survival (19 versus 12 months, HR for disease progression 0.62, 95% CI 0.51-0.75)",
"     </li>",
"     <li>",
"      A trend towards improvement in overall survival (17 versus 24 percent had died; HR for mortality 0.64, 95% CI 0.47-0.88)",
"     </li>",
"     <li>",
"      Significant improvement in overall response rate (80 versus 69 percent)",
"     </li>",
"     <li>",
"      Higher rates of diarrhea (67 versus 46 percent), neutropenia (53 versus 50 percent), rash (34 versus 24 percent), mucosal inflammation (27 versus 20 percent), serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      febrile neutropenia (14 versus 8 percent), and dry skin (10 versus 4 percent)",
"     </li>",
"     <li>",
"      Similar rates of left ventricular dysfunction (1 versus 2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    compared to placebo on progression-free and overall survival was presented at the 2012 San Antonio Breast Cancer symposium, after 69 percent of the planned events for the final analysis were recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/50\">",
"     50",
"    </a>",
"    ]. The median PFS was consistent with the original study results. However, OS had not been reached in those patients treated with pertuzumab; it was 38 months in those treated with placebo. No new safety signals were reported with longer follow-up.",
"   </p>",
"   <p>",
"    These data support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    as a first-line treatment option for patients with HER2-positive metastatic breast cancer, particularly if they have not previously seen HER2-directed therapy in the adjuvant setting. However, this combination has not been compared to T-DM1 or other trastuzumab-containing regimens to inform whether it should be a preferred regimen in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H726453560\">",
"    <span class=\"h3\">",
"     Second-line setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data to support the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for patients who progress after prior trastuzumab-containing treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 66 patients previously treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus an anthracycline (n=46) or a taxane (n=27) received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      plus trastuzumab [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/47\">",
"       47",
"      </a>",
"      ]. The objective response rate was 24 percent, including complete responses in five patients. The median PFS was 5.5 months. Minimal cardiotoxicity was reported. Overall survival was not reported.",
"     </li>",
"     <li>",
"      In a separate trial, 29 patients received single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      following disease progression on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/51\">",
"       51",
"      </a>",
"      ]. Following progression, 17 patients continued pertuzumab with the addition of trastuzumab. During monotherapy with pertuzumab, the ORR was 3 percent and the median PFS was seven weeks. For those patients who went on to receive trastuzumab in combination with pertuzumab, the ORR was 18 percent and median PFS was 17 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies support the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for patients who progress on prior treatment with trastuzumab. Pertuzumab appears to be a much more active agent when combined with trastuzumab than when it is administered as monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111524024\">",
"    <span class=\"h1\">",
"     VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of vascular endothelial growth factor (VEGF) inhibitors are being developed in breast cancer, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541989007\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    , a monoclonal antibody against vascular endothelial growth factor (VEGF), acts as an inhibitor of angiogenesis. As monotherapy in metastatic breast cancer, it has only modest activity (response rate of 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/52\">",
"     52",
"    </a>",
"    ]. However, in combination with chemotherapy, increased activity has been seen.",
"   </p>",
"   <p>",
"    Despite this, and given the inability to select patients most likely to benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , the associated toxicity risks, and the lack of overall survival seen when combined with chemotherapy, some experts prefer not to include it in the treatment of patients with metastatic breast cancer. However, others believe that combination of weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and bevacizumab is still a reasonable option for patients with metastatic breast cancer as suggested by the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing treatment was best demonstrated in the Eastern Cooperative Oncology Group trial (E2100), 722 patients (overwhelmingly HER2-negative) without prior treatment for metastatic breast cancer were randomly assigned to bevacizumab (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on days 1 and 15) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1, 8, and 15 of every 28-day cycle) or paclitaxel alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/54\">",
"     54",
"    </a>",
"    ]. Bevacizumab combined with paclitaxel resulted in a significantly increased ORR (37 versus 21 percent) and PFS (12 versus 6 months) compared to paclitaxel alone, but there was no significant increase in median survival (27 versus 25 months). Likewise, PFS was increased when bevacizumab was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (AVADO trial) and investigator-selected chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , a taxane-based, or an anthracycline-based chemotherapy) in the RIBBON-1 (first-line) and RIBBON-2 (second-line) trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. In a pooled analysis of data for bevacizumab and first-line chemotherapy from E2100, AVADO, and RIBBON-1, the addition of bevacizumab significantly improved median PFS (9.2 versus 6.7 months), but not overall survival (26.7 versus 26.4 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/58\">",
"     58",
"    </a>",
"    ]. Without an overall survival advantage, it is unclear whether the magnitude of improvement in PFS (2.5 months in the above analysis) is clinically meaningful given the excess toxicity and expense of adding bevacizumab.",
"   </p>",
"   <p>",
"    Preliminary United States Food and Drug Administration (FDA) approval was granted for the combination of first-line",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    based on the E2100 trial. However, in November 2011, the FDA revoked the approval of bevacizumab as a first-line treatment for metastatic breast cancer because no study has shown an improved overall survival advantage when combined with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, subsequent studies (AVADO and RIBBON-1) did not replicate the magnitude of benefit in PFS seen with weekly paclitaxel in the E2100 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the FDA decision to withdraw approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in metastatic breast cancer, the evidence discussed above supports the use of the combination of bevacizumab and weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in HER2-negative metastatic breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111524031\">",
"    <span class=\"h2\">",
"     Small molecule VEGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another strategy for targeting VEGF and tumor angiogenesis is the use of small molecule receptor tyrosine kinase inhibitors that target the VEGF receptor (VEGFR), including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , and motesanib. However, there are no published trials to date that demonstrate improvement in survival when these agents are used to treat metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, 229 patients with advanced or metastatic breast cancer were treated with first- or second-line combination therapy consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    orally twice a day for 14 days of a 21-day cycle) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (400 mg orally twice a day) or capecitabine plus placebo with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small increase in progression-free survival with the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (median, 6 versus 4 months with capecitabine plus placebo, hazard ratio [HR], 0.58; 95% C 0.41-0.81).",
"     </li>",
"     <li>",
"      No significant difference in overall response rate (38 versus 31 percent, respectively) or overall survival (median, 22 versus 21 months, respectively, HR, 0.86; 95% CI, 0.61 to 1.23).",
"     </li>",
"     <li>",
"      A higher rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hand-foot syndrome with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      compared to placebo (44 versus 14 percent). Treatment with sorafenib was also associated with higher rates of toxicities (of any grade) including rash (22 versus 8 percent), diarrhea (58 versus 30 percent), mucosal inflammation (33 versus 21 percent), neutropenia (13 versus 4 percent), and hypertension (18 versus 12 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until more clinical experience has been obtained, we do not administer these agents in the setting of metastatic breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111524038\">",
"    <span class=\"h1\">",
"     EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although single agent activity of epidermal growth factor receptor (EGFR) inhibitors, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , in refractory metastatic breast cancer is limited, these agents are being investigated in combination with chemotherapy. Of note, cetuximab combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    may have modest activity in patients with triple-negative metastatic breast cancer. These agents remain investigational and should not be used outside of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link&amp;anchor=H98882405#H98882405\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Epithelial growth factor receptor inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111524045\">",
"    <span class=\"h1\">",
"     PARP INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poly (ADP-ribose) Polymerase-1 (PARP-1) is a DNA-binding protein involved in detection and repair of DNA strand breaks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/65\">",
"     65",
"    </a>",
"    ]. Pharmacologic inhibitors of PARP are being investigated as chemotherapy sensitizers for the treatment of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Cancers defective in DNA repair, specifically cancers with mutations in the breast cancer associated (BRCA)1 and BRCA2 genes and triple-negative breast cancer (which shares molecular and pathologic features with BRCA1-related breast cancers) appear to be particularly sensitive to inhibition of PARP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/43/22202/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Further discussion of PARP-inhibitors in the treatment of triple-negative breast cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PARP inhibitors are being tested as single agents in BRCA1-associated cancers and in combination with chemotherapy in triple-negative breast cancer (ie, lacking expression of the estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2] protein).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111524052\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel biologic therapies that specifically target molecular pathways, such as growth factors relevant to the development of breast cancer, have contributed to advancing the treatment and improving survival in metastatic breast cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer receive HER2-directed therapy as first-line treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H111523989\">",
"       'HER2-directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with hormone receptor- and HER2-positive metastatic breast cancer that is not rapidly progressive or symptomatic, and those without significant visceral involvement (ie, multi-organ metastases), we suggest HER2-directed therapy in combination with endocrine therapy rather than in combination with chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link&amp;anchor=H19266990#H19266990\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'HER2-positive breast cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For all other patients, we suggest HER2-directed treatment plus chemotherapy rather than single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest trastuzumab plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, trastuzumab monotherapy and other trastuzumab combinations with chemotherapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , platinum compounds, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ), or in combination with other biologics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      ) represent reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H111523996\">",
"       'Trastuzumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H104779603\">",
"       'First-line treatment with trastuzumab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who progress during or within six months of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      and patients who progress following treatment with a trastuzumab-based regimen for metastatic disease, we recommend continued HER2 blockade (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest T-DM1 for these patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, if T-DM1 is not available, reasonable options include an alternative trastuzumab-plus chemotherapy regimen, trastuzumab plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      , or a lapatinib-containing regimen. (See",
"      <a class=\"local\" href=\"#H111525572\">",
"       'Second or later line treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H726455386\">",
"       'Lapatinib'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1210541131\">",
"       'Lapatinib plus trastuzumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H720673240\">",
"       'Ado-trastuzumab emtansine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific chemotherapy recommendations in metastatic breast cancer are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/1\">",
"      Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years. Cancer 2013; 119:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/2\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/3\">",
"      Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/4\">",
"      Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/5\">",
"      Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/6\">",
"      Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/7\">",
"      Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/8\">",
"      Yip AY, Tse LA, Ong EY, Chow LW. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 2010; 21:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/9\">",
"      McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/10\">",
"      Harris CA, Ward RL, Dobbins TA, et al. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2011; 22:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/11\">",
"      Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/12\">",
"      Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/13\">",
"      Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/14\">",
"      Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/15\">",
"      Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/16\">",
"      Krell J, James CR, Shah D, et al. Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. Clin Breast Cancer 2011; 11:153.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves new treatment for late-stage breast cancer. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm (Accessed on February 22, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/18\">",
"      Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/19\">",
"      Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25:3853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/20\">",
"      Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/21\">",
"      Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/22\">",
"      O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004; 5:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/23\">",
"      Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/24\">",
"      Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/25\">",
"      Hamberg P, Bos MM, Braun HJ, et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/26\">",
"      Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 2004; 90:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/27\">",
"      Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/28\">",
"      Baselga J, Carbonell X, Casta&ntilde;eda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/29\">",
"      von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/30\">",
"      Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/31\">",
"      Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2011; 29:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/32\">",
"      Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/33\">",
"      Hurvitz SA, Dirix L, Kocsis J, et al. Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol 2013; 31:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/34\">",
"      Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26:5544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/35\">",
"      Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/36\">",
"      Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/37\">",
"      Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/38\">",
"      Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/39\">",
"      Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/40\">",
"      Reddy N, Cohen R, Whitehead B, et al. A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmacol Ther 2007; 81:S16-S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/41\">",
"      Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 2007; 25:3397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/42\">",
"      Crown JP, Burris HA 3rd, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 112:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/43\">",
"      Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/44\">",
"      Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012; 23:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/45\">",
"      Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/46\">",
"      Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/47\">",
"      Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves Perjeta for type of late-stage breast cancer. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm307549.htm (Accessed on June 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/49\">",
"      Baselga J, Cort&eacute;s J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/50\">",
"      Swain SM, Kim S-B, Cortes J, et al. P5-18-26. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012; 72:476s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/51\">",
"      Cort&eacute;s J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/52\">",
"      Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30:117.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guideline in Oncology: Breast Cancer. Version 2.2011. file://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/54\">",
"      Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/55\">",
"      Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/56\">",
"      Robert NJ, Di&eacute;ras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/57\">",
"      Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29:4286.",
"     </a>",
"    </li>",
"    <li>",
"     O'Shaughnessy, J, Miles, D, Gray, RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28:7s (abstr# 1005).",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm (Accessed on December 08, 2011).",
"    </li>",
"    <li>",
"     FDA begins process to remove breast cancer indication from Avastin label. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/61\">",
"      Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012; 30:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/62\">",
"      Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/63\">",
"      Martin M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/64\">",
"      Baselga J, Segalla JG, Roch&eacute; H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; 30:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/65\">",
"      Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008; 8:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/66\">",
"      Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/67\">",
"      Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/68\">",
"      Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/43/22202/abstract/69\">",
"      Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103:334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15749 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22202=[""].join("\n");
var outline_f21_43_22202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H111524052\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111525243\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111523989\">",
"      HER2-DIRECTED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226705306\">",
"      Treatment selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H597117472\">",
"      Approach to patients previously treated with adjuvant trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H803307141\">",
"      - The treatment-free interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111523996\">",
"      Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1210541765\">",
"      - First-line treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28338387\">",
"      Trastuzumab combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1143301234\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1143300768\">",
"      - Trastuzumab plus multiagent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1143300749\">",
"      - Combination versus sequential therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1143301128\">",
"      Trastuzumab monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111525572\">",
"      - Second or later line treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111525586\">",
"      - Trastuzumab dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1210542579\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H720673240\">",
"      Ado-trastuzumab emtansine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H720673490\">",
"      - First-line treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H726455386\">",
"      Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1210541060\">",
"      - First-line treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1210541067\">",
"      - Second or later line after trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H720673013\">",
"      Lapatinib plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1210541131\">",
"      Lapatinib plus trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111525688\">",
"      - Lapatinib dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1210541101\">",
"      - Toxicities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H627738343\">",
"      - Progression following lapatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104779482\">",
"      Pertuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104779603\">",
"      - First-line treatment with trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H726453560\">",
"      - Second-line setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111524024\">",
"      VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541989007\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111524031\">",
"      Small molecule VEGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111524038\">",
"      EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111524045\">",
"      PARP INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111524052\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_43_22203="NCCN risk factors for cutaneous SCC recurrence";
var content_f21_43_22203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features identified by the National Comprehensive Cancer Network as risk factors for recurrence of cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Location/size*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly-defined borders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressed patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Site of previous radiation therapy or chronic inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapidly growing tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderately or poorly differentiated tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoid (acantholytic), adenosquamous, or desmoplastic subtypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depth &ge;2 mm or Clark level IV or V",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineural or vascular involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Size &ge;20 mm on trunk or extremities; size &ge;10 mm on cheeks, forehead, scalp, or neck; size &ge;6 mm on \"mask areas\" of the face (central face, eyelids, eybrows, periorbital nose, lips [cutaneous and vermilion], chin, mandible, preauricular and postauricular skin/sulci, temple, ear, genitalia, hands, and feet).",
"    </div>",
"    <div class=\"reference\">",
"     Source: Miller SJ, Alam M, Anderson J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Basal Cell and Squamous Cell Skin Cancers, 2nd ed, National Comprehensive Cancer Network, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22203=[""].join("\n");
var outline_f21_43_22203=null;
var title_f21_43_22204="Complications associated with multiple cesareans";
var content_f21_43_22204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of complications associated with cesarean delivery according to the number of previous cesarean deliveries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Number of previous cesarean deliveries",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Risk of complications, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Placenta accreta",
"      </td>",
"      <td class=\"subtitle2\">",
"       Hysterectomy",
"      </td>",
"      <td class=\"subtitle2\">",
"       Transfusion",
"      </td>",
"      <td class=\"subtitle2\">",
"       Cystotomy",
"      </td>",
"      <td class=\"subtitle2\">",
"       Bowel injury",
"      </td>",
"      <td class=\"subtitle2\">",
"       Maternal death*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0.24",
"      </td>",
"      <td>",
"       0.65",
"      </td>",
"      <td>",
"       4.05",
"      </td>",
"      <td>",
"       0.13",
"      </td>",
"      <td>",
"       0.11",
"      </td>",
"      <td>",
"       0.19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       0.31",
"      </td>",
"      <td>",
"       0.42",
"      </td>",
"      <td>",
"       1.53",
"      </td>",
"      <td>",
"       0.09",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       0.07",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       0.57",
"      </td>",
"      <td>",
"       0.90",
"      </td>",
"      <td>",
"       2.26",
"      </td>",
"      <td>",
"       0.28",
"      </td>",
"      <td>",
"       0.13",
"      </td>",
"      <td>",
"       0.05",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       2.13",
"      </td>",
"      <td>",
"       2.41",
"      </td>",
"      <td>",
"       3.65",
"      </td>",
"      <td>",
"       1.17",
"      </td>",
"      <td>",
"       0.34",
"      </td>",
"      <td>",
"       0.07",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       2.33",
"      </td>",
"      <td>",
"       3.49",
"      </td>",
"      <td>",
"       4.26",
"      </td>",
"      <td>",
"       1.94",
"      </td>",
"      <td>",
"       0.00",
"      </td>",
"      <td>",
"       0.00",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       6.74",
"      </td>",
"      <td>",
"       8.99",
"      </td>",
"      <td>",
"       15.73",
"      </td>",
"      <td>",
"       4.49",
"      </td>",
"      <td>",
"       1.12",
"      </td>",
"      <td>",
"       0.00",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only two of the 27 maternal deaths were potentially related to the cesarean delivery itself. Both occurred in women having their second cesarean delivery.This study did not have adequate power to determine whether rare but serious events, such as maternal death, increased as the number of cesarean deliveries increased.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Silver, RM, Landon, MB, Rouse, DJ, et al. Maternal Morbidity Associated With Multiple Repeat Cesarean Deliveries. Obstet Gynecol 2006; 107:1226.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22204=[""].join("\n");
var outline_f21_43_22204=null;
var title_f21_43_22205="Prolonged benefit of nasal CT";
var content_f21_43_22205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcitonin chronically preserves bone density",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean percent change in lumbar bone mineral density (BMD) in 87 postmenopausal women treated with 500 mg of calcium/day alone or with intranasal salmon calcitonin (sCT, 50 IU/day). Both treatment regimens were given for five days each week. sCT preserved BMD whereas there was a gradual decline with calcium alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Reginster, JY, Meurmans, L, Deroisy, R, et al. Eur J Clin Invest 1994; 24:565.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22205=[""].join("\n");
var outline_f21_43_22205=null;
var title_f21_43_22206="NuvaRing PI";
var content_f21_43_22206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    NuvaRing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ring stays inside the vagina for 3 weeks at a time. It delivers hormones into the body that help prevent pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.nuvaring.com. Copyright &copy; 2004 Organon USA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22206=[""].join("\n");
var outline_f21_43_22206=null;
var title_f21_43_22207="Fastrach";
var content_f21_43_22207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fastrach&trade; or intubating LMA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 369px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFxAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKpX2qWNiwW7uoo5DyIy2XP0UcmgC7RXPy+LNOjYgC5YDuYiv/oWKdF4q06RgD56g9zHuA/75zQFjeoqtZX1reputJ45QOoU8j6jqKs0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUdT1S209f3zFpSCywpguw9cdh7nAHc1Q1fWGSRrTTvnuPutIBuEbf3VX+J/bgDqxA6s0rQVVzcaj+9lchyjHdlh0Ln+Nh2/hXsO9AyuZNY1snyGFlZkcMpI3e+7hm/4DtH+0as6f4VsLZW87dO7nc+TsVj7gdf+BZPvW/RQFytBp9nb/wCotLeP/cjApJtOspwRNaQPnuUGatUUCObv/DEe8T6bI0M6fdBY/o3Vf1HtTtF1mUXP2DVhsuQ21JCAN5/usBwG9COD29K6KsPxVpqXli84VvNhXJ2cMyDkgH1HUHsR70DNyisrw1ftqGlq0zq9zEfKmKjAZgB82PRgVb/gVatAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyNVvZHk+xWJPnMcO6nle+0f7WO/Yc+gM+r3jW0QigP+kSfdIXdtHdsd+oAHckCl0qyFrFucHzn5Yk5Iyc4z3OeSe5/CgA0vTYrGMYAMuMbh0UZzge2eT3J5NX6KKACiiigAooooAKKKKAOX8OKLPXb2zXhGUkD02Pgf8AjkiD8K6iuZsPm8Y3BHHyzfytx/OumoGwooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU2R1jjZ5GCooLMT2Ap1ZmsOZDFapgmQ7mz6A8A/U4/AGgCDTo2u72S9mU8H5FPb0H4A/99MfStqobaNY4winIUYyepPc/jU1ABRRRQAUUUUAFFFFABXL+P8AVjYaULWBmF1dny12feC9yPfsPrXTswVSzEBQMkntXmBu21rxJdas5zZ2YK24PRiDhf8Ax4Fv+ArQNGho811Y6lBkrPOIys5b5sDOWwc9c4H4Cuv0vWLPUpZ4raVTNAcSR55U/wD6+PrXCXF8NJ0C61JiBPKMQBvU8J/VjW58MtFbS9BFzc7jeXuJXL/eVf4VPvySfdjSWuoM7CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCC9uFtLSadxkRqWx6+1cnaar53ieK2cv5zQvcOoGVUDCgZ7D5jj1NXdW1SO9Zra3G6BWBeQHhiDnA9sjr7VjaHYmDXb66klEklyUVABjZEv8PudxJJ+lcrqOdVRi9DoUFGDctzvYv8AVrj0p1Igwij2pa6jnCiiigAooooAKKKRmCqWYgKBkknAAoA5L4kaz/Zui/ZYWb7VeZjUJ94L3IHr2H1rnltRaxWWjqoEpG+42nIU4GR+Awv4iufn8TLrHjC41W4s7yS005ykVuiKznaTscLnJTPzEjJBAGK07HWLe10vV9Zkube4vUQO0Kvlogxwm5fvAM+eSO2O1JvSyNOVotvaDxD4stNNI3Wdj+9nHYnjj+S/i1eogYGBwK434XaTJZeHxqF5k32pEXEhYchTyo/I5+rGuyp7aEMKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzvjDUDBbRWULETXWQxB5WMY3H8cgfia6KuA1ub7X4wvEySLWOOHHpkbz/AOhCufFTcYaddDahHmld9CSFRHCqgYGOlPsJD/asWOyNn81x/WoJ5QiEkgUvhdvtupXMy/6tHECHHUryxH/Amx/wE1y0Feokb1PgbO9X7o+lLQBgAUV6RxBRRRQAUUUUAFef/GXxF/Y3hr7FA2LvUiYVOM7U/jPIIPHGDjOTg5rv2YKpZiAoGSTxivnfW9SbxZ48utS5aysf3VrkfeAPB6ZIJBbgkEAUFwV2VIlTTdBNvOF8uFGkdCpfaQuWYAfOuAMcZHFcX4T8NxeN/iDo8Gm3+oxafqdkl3q0EziYNGgPyhkPA2uiDPKs2eCMDsb65SKSS7ba1vYYkQuRsaUn92uT8uS2CcMjYyR0rvf2dPBdt4c8KS6uLZYbrWSJwBu+SAZ8sAEnG7LPjP8AGB2qFq7mk3ZHrEaLHGqRqFRQAqqMAAdhTqKKswCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADxzXmtlqml6lqupX+kTQXy3Lq5+zzq8nCKvzR53D7vTHau91m8/s/Srq64zFGWUHu3YfnivMdV0rTJdJA1Gytrlwud7xjfuPcMOQe/Brhxk9kvU68LFO7fXQpa1ezXurxWGnzeXdSkqEkXDRKOWkZTzgDt3OBXpHhXTY7KziSJSsUahUBOT9T6knkmvLPhbpd5da1e3w1S8fT4HazjtJT5oY4Vid7fMFGRwO/ftXuEMYijVR2FXg4WhzvdhjJe97NbL8x9FFFdZyBRRRQAUUUUAcF8YvEf9ieF3tbZyL/UcwRbD8yr/ABvwc8A4yAcFhxivMPs8fhzQ7SJkUSyDzGjGPnkPOMDAOBgZG0g5q9ql+PGXxDub5pA2kaZ8kOeUbaTyOcElgT/C2BjniqvivVbfTI5NT1ATTSJsDW6FTMxdsRQhWOcnBYh0cFVIzWc5W0OiEbIp6doT+IPFWl+G2WQYzd6q2Cr7MDcjHCSAbSI8HeAZGweK+k0VY0VEUKijAAGABXnfwU8Ptp3h+XWLtQL7WCLggLtCRclAAOBnJbgD7wBHFei1cVZGVR3YUUUUyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7xDCJ9GuUYgAqDyMgkEEA/U1wmvWzpbeSLdpHkG1Vt/vE+gB4rvNaLC2XCsY94LlQTgDnoOeuKw9PEeo6yhjZJI4VLkg55PA/maGk1ZjjJp3QfD3Q/7G8P2sMikTYMsuQAfMc7jn3GQPwrrKaihFAHanUkklZBKTk22FFFFMQUUUUAFcN8YPEI0PwlNDE4W8v8ANvFnHAI+Y88cDtkdeK7mvCNZvh4u+JU9wedK0YFAeRnaee3RmGeQQQOtJlwV2P0XSTpOgxWvlk3Uieddbt3A7K/ysQvQfMGHB5Fch4cih+I3juHQBBLc6PpF091JewXgNvNwgYNEN6D7ropRlGGDAcHPX+KPLl02WO4ubmzebEqS28yQSoQRsMTOVwc7RuifjPzLgmur+B3hmXRvD1zqeo3Ml7qOry+e1zNCsczRD7m8j7xOWbcck7h6VlH3ndmsnyo9IVQqhVACgYAHQCloorY5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApMAEnAye9LRQAUUUUAFFFFABRRRQBx3xV8Rf8I74SuHhcreXX7iAg4Kk9Wzg4wO5GMlc9a888J6V/ZmgWtsYz590PtMyhcnHUKqj27Ic8njtSeLLseMfiSICd2k6RnOejY+8R65bAyp6DkcVY17Ura0spJ7+WFIrlir+cV2NgEiI7lZC5C8I4Qnna2azqOysbwVitFaP4g8UW+kwSFFuHEt8I3wREByGAMbA4yMyRFgzqCTwa9zijSGJI4kVI0AVVUYCgdABXCfCbSZINLn1W7JMt837pd7MEiHTGXYcnoVwCqx5GRXfVUFZGdR3dgoooqiAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqmpaja6bbme8lEaZwo6s59FA5J9hUOs6mmmxRgRtPdztst7dD80rf0A6kngCuU0myuvEF899Jct5QzG97Fld/rHa5+5GOhl+8x6Y4NOwy7deJ55bn7PBE8Ep6QLGZ7rB5BaNeIwfVyKeIdeuwHEEsQIz/pN+I2/75jjYD866LTrC1021W3sbdIIRztQdT3JPUk9yeTVqkFzkzFr1oC2ZyB/clFwPyZVb8s1b03xGkjiLUFWJi20SrkJn0YHlT9a6GszWNKjvomdFVbkDAYjhh/db1H8qBGnRWF4ZnZYjaSsxCcRh/vKBwUJ74P6Vu0AFct8SvEH/AAjvhS7uYnxdyjybcc53nvxzwMnIzjFdTXifji7/AOEs8eRWAIbSdLzvPBV3HLdeDyAuQQw5z1pMqKuyp4Q00adoSCUjzr8+fOWZR8v8KnOFJPvtPJ71zurabfeM/iLo2iX+naha2Edw8heWFJYZYUyd5YgSwNjO1GLAFlI4bJ7bULpo4ZZx5u5vv+UrM6R9h8qsVz2DoyEnGRmtv4U6OLe1udVkijSa9bZGIwAojU84CqoALDA+UfKi1kvelc2k+VXPQ7eNIoUSNdsaKFUDsB0FS0AYGBRWxzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQXt1DY2c11cuEghQu7egFT18y/Fn4zXWn/ABDmstPihutG0l/JlgkyFuLhSCzHofkYBQOmVY85GN8Php4iTjDpqROpGmryPV4YLjxFq9yt5uSIqFvsHBijb5ks1I6MwIeQ+jKO/HfwRrFEiIioiqFVFGAoHQAelc18Pcz+FdJuJY2jmuLdbuZX+/5sv7xi3+1lua6mspaOxd7hRRRUgFFFFAGBOv2XXyy8LJsl/EnY39DW/WFrJ/4mcYHXyD/6GuK3TSQGB441weH/AA5dXan/AEph5VsgG5nkI4wuQWxydoOSAcc15loNh9g0xRM4+0XP725kL5HvliOfTLjOAMk4rR8Z3/8AwkHjWOxjYNpulAmboUkmz0PVTggfKwVhsJB5rO1/WYtH06S7c7rkg+RbJNsmmIGdkfzB9x9QHA6kYrKcuhvCNkVb63l1rWrHTBGwSVxsd4tyomCcqWR1HClvkl2ttHANezaTBHBBHHAmyGJBHGv91QMAfkK8n+CemamdIk1jxFHGurXkjoB9jS2kjjBAYOqqvzF1xyOi+5z7JAmyMCrgrIipK7sSUUUVZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJ5o4IZJp5EjijUu7uQFUAZJJPQU+vnP9qPxzKskPg3TZVWOSNbjUmXBJBOY4s546bmGORs5wSDvhsPLEVFTiZ1aipxcmP8AH37Qbx37Wfgi2gmgjJEl/eIxVz/0yQEcdPmbr/dxyfFPh3pFlrXxF0Gz1u4U2U9zukEmSbh+WWM/77YUn/aNYfCqB+dWvD1zJa+J9HuYtxlhvoJEA6kiRSK+qWDp0aMo09NN+p5KxEqlSLl3PvrS0YW+9/vyHcauVXsnDRsB0DEfrVivjj2gooooAKKKQkKCSQAOSTQBh3Z87XGA5CeVEfrkuf0ApfGWtLoHh27viwEwXZCDg7pDwoAJGfXGecU3RQbi6+0HPzFpz/wLhR/3yK4L4j3f9v8Aiq00eMlrG0JNxjlWbALA9QcAqNrAffyDwaRUVdmR4ZtXt9LE9wT9rvT50zux3Y7Asw3YAxw2cEnmq3iCxXxBc2+jzW0c1rK4KiaAvGuQcMpaOSPOAzbo3TcFZcA4rauLhbeCWbcqlVJQc5CgdQFYPjHddxHoad4C04yTXOqXMGy6nYoC8aq46b8ny427KvIPKsc/NWKXNI2k7K533hywhtLW3trSLyrW2jSGFB0VFAVR+QFdCOlVNPiEcIq3W5zhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfBXxE1GTVfiJ4mvZZGk36hOiM39xHKIPwVVH4V92393FYWNxd3JYQW8bSyFULkKoJOFUEk4HQAk1+f3iW4gu/EWtX2nq50+5vZ57d2GD5byFlyOxwRxXt5KrTlLyOHHfAkUXfqc9a6b4VaVJrfxE0S3VS0UFwt5OcZAjiO859MkBR7sK5OFZry5htrOKSe4lYJHFEpZnY9AAOpr6i+DPgVvCelO96I31m+2m5ZTkRKPuxK3fBOWI4J9QoJ9DMMZGlTaW7ObC0HKSk9ke0aISbfLdTya06p6cgSEYFXK+UPXCiiigArM1+XFj9nVtr3TeSD6KfvH8FBNadczev/aWtmJSdik2yH26zN+W1PrmhjRLPfx6L4budSkXlhujjJALE4WNBkjr8o6968u0RJXt5b25fdc3pPzsCDsySTyMgFixwxOMgA4Ara+Kmovqeu6f4bspAIU+e6Cgkcr93uOEJJUj+NSOlVkdIw0q4EcK7UCAttRB1wpDkDnpk49azm7I2grK5z2v6qZ/EemeG7a3mnN6v2hnTY0MSjO0uGEiH5kzkbTgEHrx6p4dsY7eKGGBQsMKhEUDHAHoK8x+Gvh+4TV9R1/Vrr7dqFyq28c0tkIJUUAbg52qXOFjG4r2PXJr2jSodka8VUFZEVHd2NKNdqAU6gdKKozCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorzj4+eMJPB/wAPLuaxnMOqXzCztGX7yM33nHII2oGIPZttXTpupNQjuxSairsT49eNf+EO8C3C2c2zWdSBtbIKcMpI+eUYII2KcgjoxT1r4klAtwBEShA5wetaD3ck7eZeyzTS8nzJJC7c8nk5pdMFjLr2nnVJdunefH9pIU5Ee4buBz0z0r6rDYRYSk0tX/Wx5VSt7aaWyPfPgf4Nm0PSXv74WpvdRSKaMpH+8gjKk7Sx6btykgccc57e3aTZ7AOMelZOjRpMBKjKyyYdWXkEEZBHtjFdfYwgLXy1WrKrNzluz1IxUVZFuFdsYGKkoorMoKKKKAKGtXjWWnvJHgzviOIHoXPAz7DqfYGvNoPiV4V8PatJYajezJqBtw9tD5DsZUILA7gCAznnntt5rT+Jmoo4ktmm8qGNTE7jqu5cysPdYsge8gr5P8bfEC5tvEV5A9nZX1k7FzaXcefIJxjynUh4mCBFO1gDtAYEUilZLU9w8MTyakdQ1q6kje91GVlyrA4XOTjcAcZ6A4IAGDVvxK8siWelxQySJcspw0ZZCoIA5eKROXIGQwx0PWvFvDPjKK7KjwvFrCXqKXezK+ccBcswdcbgACT8ikD+91r1P4XXR8TareaxdQok8IQD9zEpBYMFyVAbdtDk7gM7lPaocbyNuZWueq+HNPS1t4IIgvlxKANqhQT3OBwMkk4HrXaWqBUFYukQgKOBW+gworQ5x1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8c/tM+Kh4h+Iv8AZttJvsdEQ2wwQQZ2wZSO/GEQj1Q19jV8mfHX4U3lj4qvNX8OPJfx6g8t7c2zAB4GZsnaejAktgdRjv1r0csnSp1uao7djDERlOFoHiUzYHFW/DGjz+IfENhpVqSsl3KIy+M7F6s59goJ/Cs65EkMrRXCPFKpwUdcEfga93/Zz8JsLabxLdR/Pc7reyz/AM8wcSSD6kbR9G9a93GYlUqTqLfocVGi3K0j3vwzaxW9vBb26lLeGNYolPJCKAoH5AV2MK7UFZWjWpijGRitgV8iz1AooooAKrajdLZWU1w4LeWuQo6seyj3JwPxqzXHeO9T8pPs6TxweWvmNLIwCxsQcMfZFDyH0CikxpXZ438UPEAhufKdgyxI9zPJnrGknzEf9dJxge1v6GvkzVbuS/1G4upTmSaQu31JzXp/xJ8RC50e4uU3xtrEw+zxN1isohtiUj1wASe5djXn/g/RLjxH4ksNLtBmW5lCZ7KO7H2AyT9KEOWrserfDPTYfDvw81LX79MSagDDEehECcyEe7EBQfb3r2v4IaJJYeEIb+8Qf2prcp1O6YgZAf8A1SZHYR4YDsZDXA61p9t4h8ZaR4J05WOj6cAl7tyMQQ4aQZHQs21M/wB6vf8ATl+bdtVc9AowFHoB2A6VMNW5F1NEonSaegCr6Vpis6yIAH9K0CQFyxwPU1ZkLRVc3luDgTIx6bUO4/kKy7nxZoNvqMdhLqtr9tkYosCvufcBnBA6HjvSuh2bNyiq6XkDoriQBW6FuB+dTRyJIMxurD1U5piHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUT3ECNteaNW9CwBrj/EPiIy38+n2jlYoTslZeCzdwD6DpWJPbrNHhQM/SuSpilF2irnTDDtq8nY9PUhgCCCD3FLXj63U2m3SRuXhDn5JEYqCfTI71s23iK/iwEvC6+kihv16/rURx0ftIp4SW6Z6PRXF2/i65BHnwQSD/AGSUP9a82+L3xY1nSr2Ox8OpFAREskssg3MpbkAYODxz+IrR4ymldBSwVWrPkR77RXhHwi+Ld/rkGoRa4qSXdiqzP5QI82EnazAE8MpxxnBzwB1r3K1uIru2jnt5FkhkUMrr0IrSlWjVWhnXw86EuWZLRRRWxgFFFFABRRRQAVx+v2syvcS3SAiRidy8gKOAPyrsKZLEsgwwoA8os/B+majBIL/S7O7W4fzttxAsm0dFAJGRx6etdxo+iR2scUccUcUUShEjjUKqKBgKAOAAOwrbitYojlVqfFO7tYbd3cbGgRcCnUUUhBRRRQBDeXMdpay3ExIjjUscdfoPevnD41a5LNbx6HDIV1HW5mgkZT/qogQ1ww59AkQ9Qsgr2nxnqYjKWkbhShEjn0bqoP0+8foK+T/iydR0671XXrgO8M8SWGlyKpIjhOSzE9mY7mJzyzE98DJ1I83LfU2jTfLzW0PJ/G+qLqmvTG34s7cC3t1HZF4FesfB2wj8GeA9Y8fahEpumjMGmo4zlj8u7Hu3HH8KvXlPgDw3N4t8W6dpEOQJ5P3r/wByMcu34AGvavijq9lqXiyy8GaXPFZaNoMZimlclUEwXDAc4Yoo2jPV2f1FXLsTD+Zl/wCAdzDpuga54o8TX8FnDfTrDFNdSANKELPJtH3myzJ0zkqfSvSNY+KOjaFLAlwkkMTEF57kbSqnnIhXMhOOQGCD3rzu8+G/iC3vPD/iXRxp2p29jawm3tbcMsjxrhkYxHjdz8208nLdSa6HwPomjaLbSSeNPsE+qyA4gEbXDj5iXeVlzvlZjjAyqhQASSTSbfQpRW71PXfBPibQfGNg914f1kaiijEkSP5Txf78YwwyQcE5BxwTXSi1jByLZc+pTJ/M1876zp+h3WriWDw+I9LVk2Q2uhG1mwB8zfaVbfuJzjoMYrRXWNPtcLb6b4gijHAD6/qKH9HxTUkS6b6HtXiNNROhXkekJ/pbIVQdMfT3r51HhDWpJzaX+iXjDLMrPGybWzncGHGfx71ut4nhU5VNUT/f8Qakw/8ARwrRtfiVf2kIit7q2jQd5Wlmb/vqSRjUTSmaU7w2PTPBcF9baXDDeReUEQKBuyeBW5JDE5zJFGT6lRn868Yb4n6kch9QsmB6gxqv6gg1n3fjSO6bfPeXqMe9nrlxB+hZx+lWnZWM3Bt3PdViCDEU08ff5ZN36Nmlja7Q/LdiQekkIJ/NSP5V8/r4ktt+X8S+MYh6Ra5DJ/6HFWg3inTp7KS0bxt43hSQbWPmWZbHs6xh1+oINO6FyM96SeVf9cin3XI/Q/41ILhO+4fUV84yahbwXguPDPj3WNOlCkCO4nmuosnqzRTeYrE/Veeld9ofxFmFoqa3p6XV0GI8/SpFWKReobZMysh7FcsM9/QuhODPVVYMMqQR6g0teQ+LfF8OpaJM2mXureGNYgO+0v7izMluH5G2dovMj8s55L8Lw3VRXDaD+1DDaWstr4x8PTrq0RZBJpbpJbzMCehZvlHTkM4PUelFxNNbn0vRXyN4u/aJ8W6xaK3g+30zTInUE7j9oukIJzncBHg+m0n3rwLX/FHiPWdR+1a5rGpXV2jEq087kxnOflGflGewwKYWP02or4P+H/7Q3jTws0UGo3I1/Tgw3RX7FpQM5O2b72ew3bgPSvp34cfHPwf42eC0S6bS9WkKoLO+wnmOccRv91+TgDhj/doEep0UUUAFFFFABRRRQB87XuryWPizWLe6JEqX0wORjILkg/kQfxrq9O1OOcDmrnxa+Htxrs41rQAp1NUCT25IUXCjoQTwHHTngjAyMCvIdM1a4srlre4V4ZYm2SRyKVZCOoIPI+hrxa1OVKbvse3S5K8E47nsriO4jKuFZSOQRkGsDUdFuIg0mlyZ7+S54/A/41U0nXUlVdxx610lveJL3BrLSW5NpUnoedXXiCeymaG6V4ZF4KSAg/rVPWbC28YQRzWN5ZxaosSxTQXMnl79vAdCeCMYyOxFeqXVrDeRFJUV1xj5gD/OuA8V+Dd8EvkabBdxEZV7ZfKniPrs+6/4cn0rNwlHzR10q9OTX2WWbIaXomhWukWEeni/MCR3c1qoOcYLlpMZYlvX9OK6bw/rV1pvy2k7LCxy0ZUMufUD19cda8S0i5ktp2t5BseI4ZTwR+HWu/0e+yqgHJPSiFVp3RWIw1lrqex2XirIH22346+ZAcg/gf6E1vWWo2l8P9FnRz3Xow/A8145/ap09DI7YhwfnKFxE3ZiBzt55/OtDRdQS/s0chVkQ7WCnO0+x9K74YyS0lqeVUwitzLQ9eorh7HW722AHm+cn92Xk/8AfXX881v2XiC0nws+bdz/AH+V/wC+v8cV2U8TCfkcc6MomzRSKQwBUgg8gilroMgooooAKKKKACiiigAqrqV2ljZyTuN23hVHVmPQD6mrVefeONejVJXDN5EGVXb/ABN0Zh787R9SaipNQjdl04Ockkcn4nvmu7j7KrbpZ8tM4/uk/MfxI2j2FZi6vaw38mjLc27XbwhnsJF3eZGwz9xhtcEA8DJxyRTbdX+eefieU7mA/hHZR7AV5br/AId1ZvF2tavf6bdalDOGa3XTb1IGSJR0ZsFxlFCBQuWLEA56+PdVZNydj2uX2cVFK53dhpumaDf6le+HLOHQNWvIfJNzFD50cfzBtwhc/L06Dj0FcLfaTJYa95VjY6RPpLXBd765jjurmRDIWzIJB8r4OMIgH161o6FOhF0+nfabXTVQQSaZeSO81ldK2WVS2cRlDn7xyew6Vv8AhHTTqWvRNIube1xM+ehIPyj8Tz+BrWlUqqXImTUp0lB1GjtodGjliWJ3nig4P2eEiFMYxtwgHAAxgcV0mmWUVpGEtYY4F6fu1x/+un2sGRnGf61r2tm7dBxXrWSPFbb3Ft/MBH7x8/7xrUt5JFA/eN/31RDpxIqylgR3piJEmb++ak8zdjcQw78CmLZkD73NSC29TSAjZIj1jj/FRTGgtz1ghP8A2zH+FWPs/P3jTTbejUAVTbWZ62tufrEv+FRvp+nt96xs2HvAp/pVw2p/vUfZT60AVG06weIxNY2hi6FDApX6YxWHeeBfDV0246NbQP8A3rXMB/JcA/iK6oW+OpNP8rjrQO7RwUngS0gO/Try7tnH3SSGx+Iwa5LV/AF2dSjvzYaTqjI4aVG2xm5XusiyIyPkfxEbh2YV7WYweo61G9rG/BFLlQ+dnjc15pWgW0kVx4Xu9BtJD+9EemRPbn6vAQPxZa4zxD4S+HnilDLZ6jb20jZwy20qLn6bCPyxX0ZLpvJaJip9jiuH8UeA9L1KRp57RrW6P/L1ZkROfdhja/8AwIGiw1JdT5p1L4DGaRzonijRGXqq3LzR5/Ex4H4mvKfE/hjWPC+ovaavaGKReQ6MJI3HXKupII+hr6r1Lwx4l0RmfT2TWLQc7Y/3c4Huh4P/AAEkn0rIg8Q2GqRSadqkKuudstrdR9D7qeVPvwaV7blciex1/wCyf8Qr3xf4Su9I1mQzahopjRZ2PzTQODs3c5LKVYE+m3OTkn3Svnj4bR6d4F1W/vtAs43i1BY1uIZH+ZQpYjy3x/tchgc4HzCvbvDfiKx8QQTPZGRJoSFmglGHjJ6ZxkEHsQSDg85BAaaZDi0bNFFFMkKKKKACuT8ceBdK8Ww7rlTbagi4ivIgN49mH8S+x98EV1lFTKKkrSKhOUHzRdmfLmv6HrPg2+SDVo/3LnEN1FzHL7A9j/snn69av6XrpTb8wAPGOcfn2/GvovULK21Czltb6CK4tpRteKVQysPcGvEvGfwwudLMl54XMtzajl7J23Sx/wC4f4x7H5uO9ebWwjj70NUetQxsavu1NGX9P1lJRgtz6GtmG5SQdQa8dstTKnaxIZTtIPBBHb2+ldFYazImBuyPQ1yKVjedDqjsNb0DS9dUHULVHmUYW4Q7JV+jjkj2OR7VzU/hG904ltMmW7i67JcJIP6N+n0rVs9cVsBjg+9bFvfxyDhgaGoyIjOrSVuhiWWyGDyJQyzMPnEg5P8A9asmwB0jVWgTi2nDNGO2OrL+HUexPpXcSCGdcSKrD0YZrE13w6NRt0W0vHtJonEsTFBIocdMjrj8ehq2k1YUaiT16liDUPLk8qcgN1HuK1oJkcDacisKPT7gQql7bwy7AB+7YkEex+8MHocdKdZRTZbyEmVk5aGbG7HqrDhh+R9QKyu4jlGMtmdVZXdxZNutZCq90PKn8K6TTNdhuSsdwPImPAyflY+x/oa4azvA/DZDDqD1q9kOOQCD611UcRKO2xyVaKe56JRXJaTrRssRXrk2o6SMeY/r7fyrrRyMivTp1FUV0cM4ODswooorQgKKKz9Z1JNOgUgB7iTKxR5+8f8AAdzQ3YErlLxPqYtbdreOQpI67pHXrGnTI/2j0FeT61I93rUlvIAsFkQGQHP7zb93/gOcfUGu4uJGstKutfvT5vlfPbo3S4nPyoSP7u4gKPx9K8/RTBF87mSZyXkkPV3JyzfiTXmY2o7KPc9PBU7XkVdZuBBp08rXcVkFAAuJUDJGSQAWBwCMkDqOtecT69dWPia3k8R6fpUE2wRLqcIlKvak5Z0IYgjJGPlPJwdtdD4xuI7zVdM0eVHe2kzd3BEe4bE3cZyMHAY8c85HIGalibgPeX85dJrt/wB3HuBWODA2AbSQeOp9h6VyRtFanocrexPqToskpCohJLOVUDccYySOp46mvR/AuhHStKzI0rXV4/2mYSPuCEj5UUdgB29Sa47wVpR1jxAvmxM1naqJ5pCRtLZ+SPHU5Iye2Aa9ks7cu/qT1NehgqVlzs87MK12qa+Zb021zzjiuitYAi5xiq1hAFVRjitMDAFdx5oAYooooAKKKKACiiigAooooAKKKKACiiigApGUMMMAR70tFAGZe6PBOCUyjfpXH+KfBdnq8e3V9PiuwBhJh8sqf7sgww/PHtXodBGRg0AfPl38O7yybOham0qDpb3xww+kijB/FR9a734WeHb/AEy4ub7VJ4BLJEIlt4WLBRnJLNwM8Dge/Nd5PYW8/LxjPqKkt7aO3TbEMClZFc7asTUUUUyQooooAKKKKACoLiLcMjgj0qeigDz7xj4O0vXmM13E0F7ji7twA5/3h0cfXn3FeTa54S1nQPMl2C8sl/5bwZOB/tJ1X9R719H3duHUnFYN3btG2VyCO4rnq4aFTXZnVRxdSlpuux89W+o5A5BHbn+ta1rqRXGx8exrvfEHhLS9VZpZYTbXJ/5b2+FJPqw6N+Iz71wmqeEdV00s9uBfW453QjDge6Hn8s159TCVKeu6PTpYylV0ej8zXtdaZQA+f6VrW+sI3UmvOIrtkOCSGHBB7GrcV5k84yPQ1z3NpUkz0uO/Ru4qdbtTjDGvOYr5hjDkY6ZOKuRao6/eNPmMnQO7mMcwG8/MOQwGCKlilVMZbNcXHrJA5Y/jUp1njOT+VF9bkOjLY666u0ZDnpjHNdP8PL6S80Fo5CW+yTNbqx7qACv5BgPwrx+fWSc811vw88XR2emzWf2ZGYTvI0jT7dxPttPQYHWujD1lCd5PQyr4aTp+6j1qiuY0zxbBe3F3B9ll8y32EmJldWDDIOSR6Glu9dnlfybYLE7dFX97Kfoo4H45r1FUi1dHmOnJOzNbVdTisFC7TLcuMpCvU+59B71gaZp8us3b3l82+BuGboJBn7iekY7n+KrOn6C8zGXUNyo5y0Zfc8h/229PYcfyrdvbqDTbCW4nIS3gTJwOgHYD9KW+stgWmi3PP/iZfCfUbPTIj+6tV+0SqOm85CD8BuOPda4e4yzbVHoAfertzcyXU9xe3GPPuHMrDPQnoPoAAB7Cub8SXhttPfynZLm4YQQFdu7zGzggMQD0PGfpzivFqz9rNyPcoU/ZxUTktSvzd6frt8HZIbyRbCzRjtLhQAzDGcnOQPqRnk1acpp2mxxzPGkdtCFdwoVeBycDAAzVaKCP+17e1t2hay0aJYUAPzCXBJYfUlgR/s89q7n4c6P/AGprovZlBtLAiTkZ3y9UH4fe/AVcYc8lBFzmqcHN9DvvB2hf2LosNs6/6XJ++uP98j7v/ARgfnXYWFuAATyTUNpCSdx6962LaPHJ7V7UUoqyPn5Scm5Pdk8KbVxUlAopkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVVurYSDIFWqKAOYvLErnArIuLYgkj8K7maESDpWPe2Y54pgefa/okGqW7LIqJc/wT7ckH0Pcj2ry+9gaxupYLuFopYztYLzg/4e9e63duRn1rjvGeh/2lZ+bAmb2EfKB/y0Tuv17j/wCvXJisP7Rc0d/zO7CYp03yS2/I83imST5YZ42b+4Tg/kamO+M/OrL9Risa7tQQTgEfSs9ru9s/+Pe4mRR/Duyv5HivJPbSvsdWsh9aGdscH9a5T/hKr+Ph7e0mPqYypP8A3yaqz+MNRYYhsbJCeAcOxJ+maLFKnJnb2Vtdajfw2VlE091McJGD19z6AdSe1eoWnwo01EUnWdUWYjMhj8rYW77cpnGa87+GvjyfSLf7PqOj20u/791aAJM3swPDfTIr1rTfHmhTKN9zPA3dZrdgR+IyK68PCg1ebV/uPOxc8TCVoRsvLW5r+H/BOk6VGc+dfSsoVpblgSQCccKAO/pXS29vBbIVt4Y4lPUIoUH8q56Lxdou3KXwc+iROf6VHc+MYcYsbWaZz0Mn7tf6n9K7VVo0lZNHmShWqO8kzqJ5o4IXlmdY40GWZjgAV5p4t1p9alEMO5NPiOVB4Mrf3iOwHYfj6UuqX15qbg3shZAcrEgwin6dz7msa+fYCDgHuB2rhxGKdRcsdjrw+HUHzPcybptpCrz7CuN1DVRc+IG0yGwhbUtKvUknW5lCvFAyAi4ix1+8AU6jjI5+XU8W+I9L0KKA6w03kXTNERCpLbcYYjkdNyjAIb5sjgHHB6N4VtLeWz1NWurWWK5eeKCC+FxA6HAVg+M4ZQARk5A7ZwOeEUlzS+R33d0o/M37S1aFmt7ZFYyzAQwxLgkkBVBz1Ynqe+a938HaH/Y2jW1kxR5ly88iDAeQ9SPYcKPYVwvww0P7TeNrFwp8uAmO2BH3nxhn/AHA9yfSvY7GAIo9a9HB0uWPO92edj63NL2cdl+ZPbQ4wMVejXApkaACpa7TzwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqOWMMDxUlFAHP6hbdTisC7hwfpXbXMIdSRWBqFqRk0wPKPF2ggSSX1qg2klpox2Pdx/X8/WuLnsEfgqDnpgV7ZdwEHivNvEXh+9guZ5bMj7CTvAjGXQdxj0HqM8V52Kw/24L1PUwWK/wCXc36HBXenLHLtEavK33Y+v4mrWn2EK3CSXEfmOqhQ2B8vrgVpwxJCMIvXqc5LfU1ZRY3OcYP615t30PWua+l2VpKBsCSY7bcEf1robXTrcf8ALPb9DXJxDbjaa1La/njHDvj607rqjGcZPZnWwW8S8YJHuasebHGmQVVfU1yg1OYjmR8e5qOW9zyzCi/YwdJvdnQ3upKBiJs+9YNzdKXBc5TOSPWs+4v1UfezWXcXTyNx0pPU1hSscTqtlreqa+umeJ5J73SZUl8i5tQipCFyyOcLhZf4CSOVbA9a7fwX4ZOoPBp1ruisLVQJpR/ADknA6BmOcAcDPTAxV7QPD13rEiuMw2efmnYcfRR/Ef0/lXq+g6VBp9olrZx7IV555ZierMe5NehQoSq2c1aP5nJiMRGheMHeT/A1NHsooIIYYYxHDEoSNB0VR0roII8DOKr2cOFAq+oAGBXpHkC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAapXVuGBwKu0EZoA5S9s8ZOOKxLu0weARXd3Fqrg4FZN3YZJ4pgeaaroFvcsX2GKQ9XQYz9R0Nc1d+H7qFiYsSr2KnB/I16zc2JHY1nT2GT93NYVMNTqatanRSxdWlondeZ5O8M8Bw6Oh9GUik82Qen516bLYHGMEgcc1VbS0Jw0UR+qiuV5f2kdkcy/mj+J5550ntx70IJ5mCxgux7KCf5V6FHpUa42wxAj/YH+FXILIqMAYGewwKSy/vL8AeZdo/icJZ+HL+6I8xRCmfvSnn8FHP8q6rSfC1jbsJJkN1L1zIPkH0Xp+ea6C3sz6da1bSyJPA4rqp4WnT1tf1OWrjKtTS9l5EFrbElQR7fSt+wtdoHHNOs7ILzjrWnGgQYFbnKEaBBT6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmPGrDkU+igCnLZq3YGqM+ngnpW1SEZoA5qTTeTjBqu2ne2RXVmNTngU0woTnFAHLDTT3X8Kmj071/lXR+QnpThEo7c0AY9vYAY4z7Vow2yr1HP8qsgYpaAEVQvSloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LMA North America, Inc. Copyright &copy; 2008 LMA North America, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_43_22207=[""].join("\n");
var outline_f21_43_22207=null;
